T.	NP	T.
Outcomes	NP	<unknown>
of	IN	of
an	DT	an
HIV	NP	HIV
cohort	NN	cohort
after	IN	after
a	DT	a
decade	NN	decade
of	IN	of
comprehensive	JJ	comprehensive
care	NN	care
at	IN	at
Newlands	NP	Newlands
Clinic	NP	Clinic
in	IN	in
Harare	NP	Harare
,	,	,
Zimbabwe	NP	Zimbabwe
:	:	:
TENART	NP	<unknown>
cohort	NN	cohort
.	SENT	.
A.	NP	A.
Data	NP	Data
on	IN	on
long-term	JJ	long-term
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
receiving	VVG	receive
antiretroviral	JJ	<unknown>
therapy	NN	therapy
(	(	(
ART	NN	art
)	)	)
in	IN	in
sub-Saharan	JJ	sub-Saharan
Africa	NP	Africa
are	VBP	be
few	JJ	few
.	SENT	.
We	PP	we
describe	VVP	describe
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
commenced	VVN	commence
on	IN	on
ART	NP	Art
at	IN	at
Newlands	NP	Newlands
Clinic	NP	Clinic
between	IN	between
2004	CD	@card@
and	CC	and
2006	CD	@card@
after	IN	after
≥10	JJ	<unknown>
years	NNS	year
of	IN	of
comprehensive	JJ	comprehensive
care	NN	care
including	VVG	include
,	,	,
psychosocial	JJ	psychosocial
,	,	,
adherence	NN	adherence
and	CC	and
food	NN	food
support.In	NN	<unknown>
this	DT	this
retrospective	JJ	retrospective
cohort	NN	cohort
study	NN	study
,	,	,
patient	JJ	patient
data	NNS	datum
from	IN	from
an	DT	an
electronic	JJ	electronic
medical	JJ	medical
record	NN	record
collected	VVN	collect
during	IN	during
routine	JJ	routine
care	NN	care
were	VBD	be
analysed	VVN	analyse
.	SENT	.
We	PP	we
describe	VVP	describe
baseline	JJ	baseline
characteristics	NNS	characteristic
,	,	,
virological	JJ	virological
and	CC	and
clinical	JJ	clinical
outcomes	NNS	outcome
,	,	,
attrition	NN	attrition
rates	NNS	rate
,	,	,
and	CC	and
treatment	NN	treatment
adverse	JJ	adverse
effects	NNS	effect
until	IN	until
November	NP	November
2016.	CD	@ord@
We	PP	we
defined	VVD	define
virological	JJ	virological
suppression	NN	suppression
as	IN	as
viral	JJ	viral
load	NN	load
&lt	NN	<unknown>
;	:	;
50	CD	@card@
copies/ml	NN	<unknown>
and	CC	and
virological	JJ	virological
failure	NN	failure
as	IN	as
&gt	NN	<unknown>
;	:	;
1000	CD	@card@
copies/ml	NN	<unknown>
after	IN	after
≥6	JJ	<unknown>
months	NNS	month
of	IN	of
ART.We	NP	<unknown>
analysed	VVD	analyse
data	NNS	datum
for	IN	for
605	CD	@card@
patients	NNS	patient
(	(	(
67	CD	@card@
%	NN	%
female	JJ	female
)	)	)
who	WP	who
commenced	VVD	commence
ART	NN	art
,	,	,
and	CC	and
were	VBD	be
followed-up	JJ	<unknown>
for	IN	for
5819	CD	@card@
person-years	NNS	<unknown>
(	(	(
median	JJ	median
:	:	:
10.7	CD	@card@
years	NNS	year
,	,	,
IQR	NP	<unknown>
:	:	:
10.1-11.4	LS	@card@
)	)	)
.	SENT	.
Median	JJ	Median
age	NN	age
at	IN	at
ART	JJ	<unknown>
initiation	NN	initiation
was	VBD	be
34	CD	@card@
years	NNS	year
(	(	(
IQR	NP	<unknown>
:	:	:
17-42	LS	@card@
)	)	)
.	SENT	.
Pre-ART	NP	<unknown>
,	,	,
129	CD	@card@
(	(	(
21.3	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
had	VHD	have
history	NN	history
of	IN	of
pulmonary	JJ	pulmonary
tuberculosis	NN	tuberculosis
(	(	(
PTB	NP	<unknown>
)	)	)
.	SENT	.
In	IN	in
care	NN	care
,	,	,
66	CD	@card@
(	(	(
11	CD	@card@
%	NN	%
)	)	)
developed	VVN	develop
PTB	NP	<unknown>
,	,	,
and	CC	and
24	CD	@card@
(	(	(
4	CD	@card@
%	NN	%
)	)	)
developed	VVD	develop
extrapulmonary	JJ	<unknown>
tuberculosis	NN	tuberculosis
.	SENT	.
385	CD	@card@
(	(	(
63.6	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
experienced	VVD	experience
≥1	JJ	<unknown>
adverse	JJ	adverse
event	NN	event
,	,	,
the	DT	the
most	RBS	most
frequent	JJ	frequent
being	JJ	being
stavudine-induced	JJ	<unknown>
peripheral	JJ	peripheral
neuropathy	NN	neuropathy
(	(	(
n	NN	n
=	SYM	=
252	CD	@card@
,	,	,
41.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
At	IN	at
database	NN	database
closure	NN	closure
on	IN	on
14	CD	@card@
November	NP	November
2016	CD	@card@
,	,	,
474	CD	@card@
(	(	(
78.3	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
were	VBD	be
still	RB	still
in	IN	in
care	NN	care
,	,	,
428	CD	@card@
(	(	(
90.3	CD	@card@
%	NN	%
)	)	)
being	VBG	be
virologically	RB	<unknown>
suppressed	VVN	suppress
,	,	,
and	CC	and
21	CD	@card@
(	(	(
4.4	CD	@card@
%	NN	%
)	)	)
failing	VVG	fail
.	SENT	.
While	IN	while
483	CD	@card@
(	(	(
79.8	CD	@card@
%	NN	%
)	)	)
remained	VVD	remain
on	IN	on
first	JJ	first
line	NN	line
,	,	,
122	CD	@card@
(	(	(
20.2	CD	@card@
%	NN	%
)	)	)
were	VBD	be
switched	VVN	switch
to	TO	to
second	JJ	second
line	NN	line
ART	NN	art
.	SENT	.
Fifty-nine	NN	Fifty-nine
patients	NNS	patient
(	(	(
9.8	CD	@card@
%	NN	%
)	)	)
were	VBD	be
transferred	VVN	transfer
to	TO	to
other	JJ	other
ART	JJ	<unknown>
facilities	NNS	facility
,	,	,
45	CD	@card@
(	(	(
7.4	CD	@card@
%	NN	%
)	)	)
were	VBD	be
lost	VVN	lose
to	TO	to
follow-up	NN	follow-up
,	,	,
25	CD	@card@
(	(	(
4.1	CD	@card@
%	NN	%
)	)	)
died	VVD	die
,	,	,
and	CC	and
two	CD	two
stopped	VVD	stop
ART.Comprehensive	NP	<unknown>
HIV	NP	HIV
care	NN	care
can	MD	can
result	VV	result
in	IN	in
low	JJ	low
mortality	NN	mortality
,	,	,
high	JJ	high
retention	NN	retention
in	IN	in
care	NN	care
and	CC	and
virologic	JJ	<unknown>
suppression	NN	suppression
rates	NNS	rate
in	IN	in
resource	NN	resource
limited	JJ	limited
settings	NNS	setting
.	SENT	.
T.	NP	T.
CLEC9A	NP	<unknown>
modulates	VVZ	modulate
macrophage-mediated	JJ	<unknown>
neutrophil	JJ	neutrophil
recruitment	NN	recruitment
in	IN	in
response	NN	response
to	TO	to
heat-killed	JJ	<unknown>
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
H37Ra	NP	<unknown>
.	SENT	.
A.	NP	A.
Tuberculosis	NP	<unknown>
is	VBZ	be
a	DT	a
fatal	JJ	fatal
human	JJ	human
infectious	JJ	infectious
disease	NN	disease
caused	VVN	cause
by	IN	by
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
(	(	(
M.	NP	M.
tuberculosis	NN	tuberculosis
)	)	)
that	WDT	that
is	VBZ	be
prevalent	JJ	prevalent
worldwide	RB	worldwide
.	SENT	.
Mycobacteria	NNS	mycobacterium
differ	VVP	differ
from	IN	from
other	JJ	other
bacteria	NNS	bacterium
in	IN	in
that	WDT	that
they	PP	they
have	VHP	have
a	DT	a
cell	NN	cell
wall	NN	wall
composed	VVN	compose
of	IN	of
specific	JJ	specific
surface	NN	surface
glycans	NNS	<unknown>
that	WDT	that
are	VBP	be
the	DT	the
major	JJ	major
determinant	NN	determinant
of	IN	of
these	DT	these
organisms'	NP	<unknown>
pathogenicity	NN	<unknown>
.	SENT	.
The	DT	the
interaction	NN	interaction
of	IN	of
M.	NP	M.
tuberculosis	NN	tuberculosis
with	IN	with
pattern	NN	pattern
recognition	NN	recognition
receptors	NNS	receptor
(	(	(
PRRs	NP	<unknown>
)	)	)
,	,	,
in	IN	in
particular	JJ	particular
C-type	NP	<unknown>
lectin	NN	<unknown>
receptors	NNS	receptor
(	(	(
CLRs	NP	<unknown>
)	)	)
,	,	,
on	IN	on
the	DT	the
surface	NN	surface
of	IN	of
macrophages	NNS	macrophage
plays	VVZ	play
a	DT	a
central	JJ	central
role	NN	role
in	IN	in
initiating	VVG	initiate
innate	JJ	innate
and	CC	and
adaptive	JJ	adaptive
immunity	NN	immunity
,	,	,
but	CC	but
the	DT	the
picture	NN	picture
as	IN	as
a	DT	a
whole	NN	whole
remains	VVZ	remain
a	DT	a
puzzle	NN	puzzle
.	SENT	.
Defining	VVG	define
novel	NN	novel
mechanisms	NNS	mechanism
by	IN	by
which	WDT	which
host	NN	host
receptors	NNS	receptor
interact	VVP	interact
with	IN	with
pathogens	NNS	pathogen
in	IN	in
order	NN	order
to	TO	to
modulate	VV	modulate
a	DT	a
specific	JJ	specific
immune	JJ	immune
response	NN	response
is	VBZ	be
an	DT	an
area	NN	area
of	IN	of
intense	JJ	intense
research	NN	research
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
based	VVN	base
on	IN	on
an	DT	an
in	IN	in
vitro	NP	Vitro
lectin	NP	<unknown>
binding	JJ	binding
assay	NN	assay
,	,	,
CLEC9A	NP	<unknown>
(	(	(
DNGR-1	NP	<unknown>
)	)	)
is	VBZ	be
identified	VVN	identify
as	IN	as
a	DT	a
novel	JJ	novel
CLR	NP	<unknown>
that	IN/that	that
binds	NNS	bind
with	IN	with
mycobacteria	NNS	mycobacterium
.	SENT	.
Our	PP$	our
results	NNS	result
with	IN	with
CLEC9A-knocked	JJ	<unknown>
down	JJ	down
cells	NNS	cell
and	CC	and
a	DT	a
CLEC9A-Fc	NP	<unknown>
fusion	NN	fusion
protein	NN	protein
as	IN	as
blocking	VVG	block
agents	NNS	agent
show	VVP	show
that	IN/that	that
CLEC9A	NP	<unknown>
is	VBZ	be
involved	VVN	involve
in	IN	in
the	DT	the
activation	NN	activation
of	IN	of
SYK	NP	<unknown>
and	CC	and
MAPK	NP	<unknown>
signaling	VVG	signal
in	IN	in
response	NN	response
to	TO	to
heat-killed	JJ	<unknown>
M.	NP	M.
tuberculosis	NN	tuberculosis
H37Ra	NP	<unknown>
treatment	NN	treatment
,	,	,
and	CC	and
it	PP	it
then	RB	then
promotes	VVZ	promote
the	DT	the
production	NN	production
of	IN	of
CXCL8	NP	<unknown>
and	CC	and
IL-1β	NP	<unknown>
in	IN	in
macrophages	NNS	macrophage
.	SENT	.
The	DT	the
CXCL8	NP	<unknown>
and	CC	and
IL-1β	NP	<unknown>
secreted	VVD	secrete
by	IN	by
the	DT	the
activated	VVN	activate
macrophages	NNS	macrophage
are	VBP	be
critical	JJ	critical
to	TO	to
neutrophil	JJ	neutrophil
recruitment	NN	recruitment
and	CC	and
activation	NN	activation
.	SENT	.
In	IN	in
a	DT	a
in	IN	in
vivo	JJ	vivo
mouse	NN	mouse
model	NN	model
,	,	,
when	WRB	when
the	DT	the
interaction	NN	interaction
between	IN	between
CLEC9A	NP	<unknown>
and	CC	and
H37Ra	NP	<unknown>
is	VBZ	be
interfered	VVN	interfere
with	IN	with
by	IN	by
treatment	NN	treatment
with	IN	with
CLEC9A-Fc	NP	<unknown>
fusion	NN	fusion
protein	NN	protein
,	,	,
this	DT	this
reduces	VVZ	reduce
lung	NN	lung
inflammation	NN	inflammation
and	CC	and
cell	NN	cell
infiltration	NN	infiltration
.	SENT	.
These	DT	these
findings	NNS	finding
demonstrate	VVP	demonstrate
that	IN/that	that
CLEC9A	NP	<unknown>
is	VBZ	be
a	DT	a
specialized	JJ	specialized
receptor	NN	receptor
that	WDT	that
modulates	VVZ	modulate
the	DT	the
innate	JJ	innate
immune	JJ	immune
response	NN	response
when	WRB	when
there	EX	there
is	VBZ	be
a	DT	a
mycobacterial	JJ	<unknown>
infection	NN	infection
.	SENT	.
T.	NP	T.
Trends	NP	<unknown>
in	IN	in
Tuberculosis	NP	<unknown>
Case	NP	Case
Notification	NP	<unknown>
and	CC	and
Treatment	NP	Treatment
Success	NP	Success
,	,	,
Haiti	NP	Haiti
,	,	,
2010-2015	CD	@card@
.	SENT	.
A.	NP	A.
Since	IN	since
the	DT	the
2010	CD	@card@
earthquake	NN	earthquake
,	,	,
tuberculosis	NN	tuberculosis
(	(	(
TB	NN	TB
)	)	)
control	NN	control
has	VHZ	have
been	VBN	be
a	DT	a
major	JJ	major
priority	NN	priority
for	IN	for
health	NN	health
sector	NN	sector
response	NN	response
and	CC	and
recovery	NN	recovery
efforts	NNS	effort
in	IN	in
Haiti	NP	Haiti
.	SENT	.
The	DT	the
goal	NN	goal
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
analyze	VV	analyze
trends	NNS	trend
in	IN	in
TB	NN	TB
case	NN	case
notification	NN	notification
in	IN	in
Haiti	NP	Haiti
from	IN	from
the	DT	the
aggregate	JJ	aggregate
data	NNS	datum
reported	VVN	report
by	IN	by
the	DT	the
National	NP	National
TB	NN	TB
Control	NP	Control
Program	NP	Program
to	TO	to
understand	VV	understand
the	DT	the
effects	NNS	effect
of	IN	of
such	JJ	such
efforts	NNS	effort
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
95,745	CD	@card@
TB	NN	TB
patients	NNS	patient
were	VBD	be
registered	VVN	register
for	IN	for
treatment	NN	treatment
in	IN	in
Haiti	NP	Haiti
between	IN	between
2010	CD	@card@
and	CC	and
2015.	CD	@ord@
Three	CD	three
regions	NNS	region
,	,	,
the	DT	the
West	NP	West
,	,	,
Artibonite	NP	<unknown>
,	,	,
and	CC	and
North	NP	North
departments	NNS	department
accounted	VVD	account
for	IN	for
68	CD	@card@
%	NN	%
of	IN	of
the	DT	the
TB	NN	TB
cases	NNS	case
notified	VVN	notify
during	IN	during
the	DT	the
period	NN	period
.	SENT	.
Patients	NNS	patient
in	IN	in
the	DT	the
15-34	CD	@card@
age	NN	age
groups	NNS	group
represented	VVD	represent
53	CD	@card@
%	NN	%
(	(	(
50,560	CD	@card@
)	)	)
of	IN	of
all	DT	all
cases	NNS	case
.	SENT	.
Case	NN	case
notification	NN	notification
rates	NNS	rate
of	IN	of
all	DT	all
forms	NNS	form
of	IN	of
TB	NN	TB
increased	VVN	increase
from	IN	from
142.7/100,000	CD	@card@
in	IN	in
2010	CD	@card@
to	TO	to
153.4	CD	@card@
in	IN	in
2015	CD	@card@
,	,	,
peaking	VVG	peak
at	IN	at
163.4	CD	@card@
cases/100,000	NN	<unknown>
in	IN	in
2013.	CD	@ord@
Case	NN	case
notification	NN	notification
for	IN	for
smear-positive	JJ	<unknown>
pulmonary	JJ	pulmonary
TB	NN	TB
increased	VVN	increase
from	IN	from
85.5	CD	@card@
cases/100,000	NN	<unknown>
to	TO	to
105.7	CD	@card@
cases/100,000	NN	<unknown>
,	,	,
whereas	IN	whereas
treatment	NN	treatment
success	NN	success
rates	NNS	rate
remained	VVD	remain
stable	JJ	stable
at	IN	at
79-80	CD	@card@
%	NN	%
during	IN	during
the	DT	the
period	NN	period
.	SENT	.
Active	JJ	active
TB	NN	TB
case	NN	case
finding	VVG	find
efforts	NNS	effort
in	IN	in
high-risk	JJ	high-risk
communities	NNS	community
and	CC	and
the	DT	the
introduction	NN	introduction
of	IN	of
new	JJ	new
diagnostics	NNS	diagnostic
have	VHP	have
contributed	VVN	contribute
to	TO	to
increasing	VVG	increase
TB	NN	TB
case	NN	case
notification	NN	notification
trends	NNS	trend
in	IN	in
Haiti	NP	Haiti
from	IN	from
2010	CD	@card@
to	TO	to
2015.	CD	@ord@
Targeted	JJ	targeted
interventions	NNS	intervention
and	CC	and
novel	NN	novel
strategies	NNS	strategy
are	VBP	be
being	VBG	be
implemented	VVN	implement
to	TO	to
reach	VV	reach
high-risk	JJ	high-risk
populations	NNS	population
and	CC	and
underserved	VVN	underserv
communities	NNS	community
.	SENT	.
T.	NP	T.
Incidence	NN	incidence
and	CC	and
clinical	JJ	clinical
profile	NN	profile
of	IN	of
tuberculosis	NN	tuberculosis
after	IN	after
allogeneic	JJ	<unknown>
stem	NN	stem
cell	NN	cell
transplantation	NN	transplantation
.	SENT	.
A.	NP	A.
Patients	NPS	Patients
post	VV	post
allogeneic	JJ	<unknown>
stem	NN	stem
cell	NN	cell
transplantation	NN	transplantation
(	(	(
alloSCT	NN	<unknown>
)	)	)
are	VBP	be
expected	VVN	expect
to	TO	to
be	VB	be
at	IN	at
high	JJ	high
risk	NN	risk
of	IN	of
tuberculosis	NN	tuberculosis
(	(	(
TB	NN	TB
)	)	)
owing	VVG	owe
to	TO	to
underlying	VVG	underlie
immunosuppression	NN	<unknown>
.	SENT	.
We	PP	we
conducted	VVD	conduct
a	DT	a
retrospective	JJ	retrospective
study	NN	study
in	IN	in
patients	NNS	patient
post	IN	post
alloSCT	NN	<unknown>
for	IN	for
clinical	JJ	clinical
features	NNS	feature
and	CC	and
factors	NNS	factor
associated	VVN	associate
with	IN	with
TB.Records	NNS	<unknown>
of	IN	of
all	DT	all
patients	NNS	patient
transplanted	VVN	transplant
from	IN	from
January	NP	January
1	CD	@card@
,	,	,
2012	CD	@card@
until	IN	until
December	NP	December
31	CD	@card@
,	,	,
2015	CD	@card@
were	VBD	be
reviewed	VVN	review
.	SENT	.
Diagnosis	NN	diagnosis
of	IN	of
TB	NN	TB
was	VBD	be
considered	VVN	consider
if	IN	if
Mycobacterium	NP	<unknown>
tuberculosis	NN	tuberculosis
was	VBD	be
cultured	VVN	culture
from	IN	from
clinical	JJ	clinical
samples	NNS	sample
or	CC	or
acid-fast	JJ	acid-fast
bacilli	NNS	bacillus
(	(	(
AFB	NP	<unknown>
)	)	)
demonstrated	VVD	demonstrate
on	IN	on
histopathology/smears	NNS	<unknown>
.	SENT	.
A	DT	a
presumptive	JJ	presumptive
TB	NN	TB
diagnosis	NN	diagnosis
was	VBD	be
considered	VVN	consider
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
signs	NNS	sign
and	CC	and
symptoms	NNS	symptom
suggestive	JJ	suggestive
of	IN	of
TB	NN	TB
with	IN	with
epithelioid	JJ	epithelioid
cell	NN	cell
granulomas	NNS	granuloma
,	,	,
without	IN	without
AFB.In	NP	<unknown>
175	CD	@card@
eligible	JJ	eligible
patients	NNS	patient
,	,	,
TB	NN	TB
was	VBD	be
detected	VVN	detect
in	IN	in
5	CD	@card@
patients	NNS	patient
(	(	(
pulmonary	JJ	pulmonary
=	SYM	=
4	CD	@card@
,	,	,
lymph	NN	lymph
node	NN	node
=	SYM	=
1	CD	@card@
)	)	)
,	,	,
with	IN	with
incidence	NN	incidence
of	IN	of
2.84	CD	@card@
%	NN	%
at	IN	at
median	NN	median
of	IN	of
258	CD	@card@
(	(	(
157-639	CD	@card@
)	)	)
days	NNS	day
after	IN	after
transplantation	NN	transplantation
.	SENT	.
Cumulative	JJ	cumulative
incidence	NN	incidence
rate	NN	rate
of	IN	of
TB	NN	TB
among	IN	among
the	DT	the
patients	NNS	patient
undergoing	VVG	undergo
alloSCT	NN	<unknown>
was	VBD	be
calculated	VVN	calculate
to	TO	to
be	VB	be
1.9/100	CD	@card@
person-years	NNS	<unknown>
.	SENT	.
Median	JJ	Median
duration	NN	duration
of	IN	of
symptoms	NNS	symptom
was	VBD	be
20	CD	@card@
days	NNS	day
till	IN	till
diagnosis	NN	diagnosis
was	VBD	be
confirmed	VVN	confirm
.	SENT	.
All	DT	all
patients	NNS	patient
were	VBD	be
started	VVN	start
on	IN	on
four-drug	NN	<unknown>
anti-tubercular	JJ	<unknown>
therapy	NN	therapy
(	(	(
ATT	NP	<unknown>
)	)	)
with	IN	with
clinical/radiological	JJ	<unknown>
response	NN	response
in	IN	in
all	DT	all
.	SENT	.
Two	CD	two
patients	NNS	patient
developed	VVD	develop
hepatotoxicity	NN	hepatotoxicity
(	(	(
transaminitis	NN	<unknown>
,	,	,
n	NN	n
=	SYM	=
1	CD	@card@
;	:	;
hyperbilirubinemia	NN	<unknown>
,	,	,
n	NN	n
=	SYM	=
1	CD	@card@
)	)	)
following	VVG	follow
ATT	NP	<unknown>
.	SENT	.
Presence	NN	presence
of	IN	of
chronic	JJ	chronic
graft-versus-host	NN	<unknown>
disease	NN	disease
(	(	(
GVHD	NP	<unknown>
)	)	)
(	(	(
P	NN	P
=	SYM	=
.008	CD	@card@
)	)	)
and	CC	and
steroid-refractory	JJ	<unknown>
GVHD	NNS	<unknown>
(	(	(
P	NN	P
=	SYM	=
.001	CD	@card@
)	)	)
was	VBD	be
found	VVN	find
to	TO	to
be	VB	be
significantly	RB	significantly
associated	VVN	associate
with	IN	with
TB.TB	NP	<unknown>
should	MD	should
be	VB	be
suspected	VVN	suspect
in	IN	in
patients	NNS	patient
with	IN	with
unexplained	JJ	unexplained
fever	NN	fever
post	NN	post
alloSCT	NN	<unknown>
.	SENT	.
Active	JJ	active
GVHD	NNS	<unknown>
and	CC	and
ongoing	JJ	ongoing
immunosuppression/steroids	NNS	<unknown>
are	VBP	be
possible	JJ	possible
risk	NN	risk
factors	NNS	factor
.	SENT	.
Early	JJ	early
diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
can	MD	can
salvage	VV	salvage
most	RBS	most
patients	NNS	patient
.	SENT	.
Hepatotoxicity	NN	hepatotoxicity
following	VVG	follow
ATT	NP	<unknown>
is	VBZ	be
a	DT	a
potential	JJ	potential
concern	NN	concern
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VVN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VVD	reserve
.	SENT	.
T.	NP	T.
Using	VVG	use
the	DT	the
theory	NN	theory
of	IN	of
planned	JJ	planned
behavior	NN	behavior
framework	NN	framework
for	IN	for
designing	VVG	design
interventions	NNS	intervention
related	VVN	relate
to	TO	to
organ	NN	organ
donation	NN	donation
.	SENT	.
A.	NP	A.
T.	NP	T.
Hantavirus	NP	<unknown>
and	CC	and
tuberculosis	NN	tuberculosis
co-infection	NN	<unknown>
in	IN	in
an	DT	an
Indian	JJ	Indian
child	NN	child
.	SENT	.
A.	NP	A.
Hantaviruses	NPS	<unknown>
are	VBP	be
a	DT	a
group	NN	group
of	IN	of
antigenically	RB	antigenically
distinct	JJ	distinct
viruses	NNS	virus
carried	VVD	carry
out	RP	out
in	IN	in
rodents	NNS	rodent
and	CC	and
insectivores	NNS	insectivore
.	SENT	.
Humans	NNS	human
are	VBP	be
accidental	JJ	accidental
hosts	NNS	host
and	CC	and
get	VV	get
infected	VVN	infect
by	IN	by
aerosols	NNS	aerosol
generated	VVN	generate
from	IN	from
contaminated	JJ	contaminated
urine	NN	urine
,	,	,
faeces	NNS	faeces
and	CC	and
saliva	NN	saliva
of	IN	of
infected	JJ	infected
rodents	NNS	rodent
.	SENT	.
Hantaviruses	NNS	<unknown>
are	VBP	be
identified	VVN	identify
as	IN	as
aetiological	JJ	aetiological
agents	NNS	agent
of	IN	of
two	CD	two
human	JJ	human
diseases	NNS	disease
,	,	,
haemorrhagic	JJ	haemorrhagic
fever	NN	fever
with	IN	with
renal	JJ	renal
syndrome	NN	syndrome
and	CC	and
hantavirus	NN	<unknown>
pulmonary	JJ	pulmonary
syndrome	NN	syndrome
.	SENT	.
Hantavirus	NNS	<unknown>
causing	VVG	cause
pulmonary	JJ	pulmonary
renal	JJ	renal
disease	NN	disease
has	VHZ	have
rarely	RB	rarely
been	VBN	be
reported	VVN	report
in	IN	in
children	NNS	child
in	IN	in
India	NP	India
.	SENT	.
Hantavirus	NN	<unknown>
infection	NN	infection
is	VBZ	be
uncommon	JJ	uncommon
under	IN	under
the	DT	the
age	NN	age
of	IN	of
12	CD	@card@
years	NNS	year
.	SENT	.
We	PP	we
report	VVP	report
a	DT	a
9-year-old	JJ	<unknown>
girl	NN	girl
from	IN	from
Mumbai	NP	Mumbai
,	,	,
India	NP	India
with	IN	with
fever	NN	fever
,	,	,
bilateral	JJ	bilateral
pleural	JJ	pleural
effusion	NN	effusion
,	,	,
thrombocytopaenia	NP	<unknown>
,	,	,
haemoconcentration	NN	<unknown>
and	CC	and
oliguria	NN	oliguria
due	JJ	due
to	TO	to
hantavirus	NN	<unknown>
infection	NN	infection
.	SENT	.
She	PP	she
also	RB	also
had	VHD	have
associated	VVN	associate
tuberculosis	NN	tuberculosis
.	SENT	.
T.	NP	T.
Critical	NP	<unknown>
physicochemical	JJ	physicochemical
and	CC	and
biological	JJ	biological
attributes	NNS	attribute
of	IN	of
nanoemulsions	NNS	<unknown>
for	IN	for
pulmonary	JJ	pulmonary
delivery	NN	delivery
of	IN	of
rifampicin	NN	<unknown>
by	IN	by
nebulization	NN	nebulization
technique	NN	technique
in	IN	in
tuberculosis	NN	tuberculosis
treatment	NN	treatment
.	SENT	.
A.	NP	A.
The	DT	the
study	NN	study
investigated	VVD	investigate
aerosolization	NN	<unknown>
,	,	,
pulmonary	JJ	pulmonary
inhalation	NN	inhalation
,	,	,
intracellular	JJ	intracellular
trafficking	NN	trafficking
potential	NN	potential
in	IN	in
macrophages	NNS	macrophage
and	CC	and
pharmacokinetics	NNS	<unknown>
profiles	NNS	profile
of	IN	of
rifampicin-oleic	JJ	<unknown>
acid	JJ	acid
first-generation	NN	first-generation
nanoemulsion	NN	<unknown>
and	CC	and
its	PP$	its
respective	JJ	respective
chitosan-	NN	<unknown>
and	CC	and
chitosan-folate	JJ	<unknown>
conjugate-decorated	JJ	<unknown>
second	NN	second
and	CC	and
third-generation	NN	third-generation
nanoemulsions	NNS	<unknown>
,	,	,
delivered	VVN	deliver
via	IN	via
nebulization	NN	nebulization
technique	NN	technique
.	SENT	.
The	DT	the
nanoemulsions	NNS	<unknown>
were	VBD	be
prepared	VVN	prepare
by	IN	by
conjugate	JJ	conjugate
synthesis	NN	synthesis
and	CC	and
spontaneous	JJ	spontaneous
emulsification	NN	emulsification
techniques	NNS	technique
.	SENT	.
They	PP	they
were	VBD	be
subjected	VVN	subject
to	TO	to
physicochemical	JJ	physicochemical
,	,	,
drug	NN	drug
release	NN	release
,	,	,
aerosolization	NN	<unknown>
,	,	,
inhalation	NN	inhalation
,	,	,
cell	NN	cell
culture	NN	culture
and	CC	and
pharmacokinetics	NN	<unknown>
analysis	NN	analysis
.	SENT	.
The	DT	the
nanoemulsions	NNS	<unknown>
had	VHD	have
average	JJ	average
droplet	NN	droplet
sizes	NNS	size
of	IN	of
40-60 nm	NN	<unknown>
,	,	,
with	IN	with
narrow	JJ	narrow
polydispersity	NN	<unknown>
indices	NN	indices
.	SENT	.
They	PP	they
exhibited	VVD	exhibit
desirable	JJ	desirable
pH	NN	pH
,	,	,
surface	NN	surface
tension	NN	tension
,	,	,
viscosity	NN	viscosity
,	,	,
refractive	JJ	refractive
index	NN	index
,	,	,
density	NN	density
and	CC	and
viscosity	NN	viscosity
attributes	NNS	attribute
for	IN	for
pulmonary	JJ	pulmonary
rifampicin	NN	<unknown>
administration	NN	administration
.	SENT	.
All	DT	all
nanoemulsions	NNS	<unknown>
demonstrated	VVD	demonstrate
more	JJR	more
than	IN	than
95	CD	@card@
%	NN	%
aerosol	NN	aerosol
output	NN	output
and	CC	and
inhalation	NN	inhalation
efficiency	NN	efficiency
greater	JJR	great
than	IN	than
75	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
aerosol	NN	aerosol
output	NN	output
,	,	,
aerosolized	VVN	<unknown>
and	CC	and
inhaled	VVN	inhale
fine	JJ	fine
particle	NN	particle
fractions	NNS	fraction
were	VBD	be
primarily	RB	primarily
governed	VVN	govern
by	IN	by
the	DT	the
size	NN	size
and	CC	and
surface	NN	surface
tension	NN	tension
of	IN	of
nanoemulsions	NNS	<unknown>
in	IN	in
an	DT	an
inverse	JJ	inverse
relationship	NN	relationship
.	SENT	.
The	DT	the
nanoemulsions	NNS	<unknown>
were	VBD	be
found	VVN	find
to	TO	to
be	VB	be
safe	JJ	safe
with	IN	with
third-generation	NN	third-generation
nanoemulsion	NN	<unknown>
exhibiting	VVG	exhibit
higher	JJR	high
cell	NN	cell
internalization	NN	internalization
potential	NN	potential
,	,	,
reduced	VVN	reduce
plasma	NN	plasma
drug	NN	drug
concentration	NN	concentration
,	,	,
and	CC	and
higher	JJR	high
lung	NN	lung
drug	NN	drug
content	NN	content
.	SENT	.
T.	NP	T.
Design	NP	Design
,	,	,
synthesis	NN	synthesis
of	IN	of
9H-fluorenone	NN	<unknown>
based	VVN	base
1,2,3-triazole	JJ	<unknown>
analogues	NNS	analogue
as	IN	as
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
InhA	NP	<unknown>
inhibitors	NNS	inhibitor
.	SENT	.
A.	NP	A.
We	PP	we
prepared	VVD	prepare
fifty	CD	fifty
various	JJ	various
9H-fluorenone	NN	<unknown>
based	VVN	base
1,2,3-triazole	JJ	<unknown>
analogues	NNS	analogue
varied	VVN	vary
with	IN	with
NH	NP	NH
,	,	,
-S-	NN	<unknown>
and	CC	and
-SO2-	NN	<unknown>
groups	NNS	group
using	VVG	use
click	NN	click
chemistry	NN	chemistry
.	SENT	.
The	DT	the
target	NN	target
compounds	NNS	compound
were	VBD	be
characterized	VVN	characterize
by	IN	by
routine	JJ	routine
analytical	JJ	analytical
techniques	NNS	technique
,	,	,
(	(	(
1	LS	1
)	)	)
H	NP	H
,	,	,
(	(	(
13	CD	@card@
)	)	)
CNMR	NP	<unknown>
,	,	,
Mass	NP	Mass
,	,	,
Elemental	NP	<unknown>
,	,	,
single	JJ	single
crystal	NN	crystal
XRD	NP	<unknown>
(	(	(
8a	NP	<unknown>
)	)	)
and	CC	and
screened	VVD	screen
for	IN	for
in	IN	in
vitro	NN	<unknown>
antitubercular	JJ	<unknown>
activity	NN	activity
against	IN	against
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
(	(	(
MTB	NP	MTB
)	)	)
H37Rv	NP	<unknown>
strain	NN	strain
and	CC	and
two	CD	two
'wild'	NP	<unknown>
strains	NNS	strain
Spec	NP	<unknown>
.	SENT	.
210	NP	@card@
and	CC	and
Spec	NP	<unknown>
.	SENT	.
192	NP	@card@
and	CC	and
MIC50	NP	<unknown>
was	VBD	be
determined	VVN	determine
.	SENT	.
Further	RBR	further
,	,	,
the	DT	the
compounds	NNS	compound
were	VBD	be
evaluated	VVN	evaluate
for	IN	for
MTB	NP	MTB
InhA	NP	<unknown>
inhibition	NN	inhibition
study	NN	study
as	IN	as
well	RB	well
.	SENT	.
The	DT	the
final	JJ	final
analogues	NNS	analogue
exhibited	VVD	exhibit
minimum	JJ	minimum
inhibitory	JJ	inhibitory
concentration	NN	concentration
(	(	(
MIC	JJ	MIC
)	)	)
ranging	VVG	range
from	IN	from
52.35	CD	@card@
-	:	-
&gt	NN	<unknown>
;	:	;
295	CD	@card@
μM	NN	<unknown>
.	SENT	.
Among	IN	among
the	DT	the
-NH-	NN	<unknown>
analogues	NNS	analogue
one	CD	one
compound	NN	compound
5p	NP	<unknown>
(	(	(
MIC	NP	MIC
58.34	CD	@card@
μM	NN	<unknown>
)	)	)
,	,	,
amongst	IN	amongst
-S-	NN	<unknown>
containing	VVG	contain
analogues	NNS	analogue
four	CD	four
compounds	NNS	compound
8e	JJ	<unknown>
(	(	(
MIC	NP	MIC
66.94	CD	@card@
μM	NN	<unknown>
)	)	)
,	,	,
8f	NP	<unknown>
(	(	(
MIC	NP	MIC
74.20	CD	@card@
μM	NN	<unknown>
)	)	)
,	,	,
8g	JJ	<unknown>
(	(	(
MIC	NP	MIC
57.55	CD	@card@
μM	NN	<unknown>
)	)	)
&amp	NNS	<unknown>
;	:	;
8q	NP	<unknown>
(	(	(
MIC	NP	MIC
56.11	CD	@card@
μM	NN	<unknown>
)	)	)
,	,	,
among	IN	among
-SO2	NN	<unknown>
-	:	-
containing	VVG	contain
compounds	NNS	compound
one	CD	one
compound	NN	compound
10p	NP	<unknown>
(	(	(
MIC	NP	MIC
52.35	CD	@card@
μM	NN	<unknown>
)	)	)
showed	VVD	show
less	JJR	less
than	IN	than
MTB	NP	MTB
MIC	NP	MIC
74.20	CD	@card@
μM	NN	<unknown>
:	:	:
Compound	JJ	compound
4-(((9H-fluoren-9-yl)sulfonyl)methyl)-1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole	JJ	<unknown>
(	(	(
10p	JJ	<unknown>
)	)	)
,	,	,
was	VBD	be
found	VVN	find
to	TO	to
be	VB	be
the	DT	the
most	RBS	most
active	JJ	active
compound	NN	compound
with	IN	with
73	CD	@card@
%	NN	%
InhA	NP	<unknown>
inhibition	NN	inhibition
at	IN	at
50	CD	@card@
μM	NN	<unknown>
;	:	;
it	PP	it
inhibited	VVD	inhibit
MTB	NP	MTB
with	IN	with
MIC	NP	MIC
52.35	CD	@card@
μM	NN	<unknown>
.	SENT	.
Further	RBR	further
,	,	,
10f	NP	<unknown>
&amp	NNS	<unknown>
;	:	;
10p	NP	<unknown>
were	VBD	be
docked	VVN	dock
to	TO	to
crystal	NN	crystal
structure	NN	structure
of	IN	of
InhA	NP	<unknown>
to	TO	to
know	VV	know
binding	JJ	binding
interaction	NN	interaction
pattern	NN	pattern
.	SENT	.
Most	RBS	most
active	JJ	active
compounds	NNS	compound
were	VBD	be
found	VVN	find
to	TO	to
be	VB	be
non	JJ	non
cytotoxic	NN	<unknown>
against	IN	against
HEK	NP	<unknown>
293	CD	@card@
cell	NN	cell
lines	NNS	line
at	IN	at
50	CD	@card@
μM	NN	<unknown>
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VVN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VVD	reserve
.	SENT	.
T.	NP	T.
Stroke	NP	<unknown>
screening	NN	screening
and	CC	and
health-related	JJ	health-related
physical	JJ	physical
fitness	NN	fitness
testing	NN	testing
in	IN	in
medical	JJ	medical
staff	NN	staff
members	NNS	member
in	IN	in
Urumqi	NP	Urumqi
,	,	,
China	NP	China
.	SENT	.
A.	NP	A.
Stroke	NP	<unknown>
is	VBZ	be
the	DT	the
leading	VVG	lead
cause	NN	cause
of	IN	of
death	NN	death
and	CC	and
disability	NN	disability
,	,	,
and	CC	and
is	VBZ	be
closely	RB	closely
related	VVN	relate
to	TO	to
a	DT	a
lack	NN	lack
of	IN	of
exercise	NN	exercise
.	SENT	.
Currently	RB	currently
,	,	,
most	RBS	most
Chinese	JJ	Chinese
medical	JJ	medical
staff	NN	staff
members	NNS	member
lack	VVP	lack
exercise	NN	exercise
and	CC	and
may	MD	may
be	VB	be
at	IN	at
risk	NN	risk
for	IN	for
stroke	NN	stroke
.	SENT	.
We	PP	we
sought	VVD	seek
to	TO	to
determine	VV	determine
the	DT	the
risk	NN	risk
factors	NNS	factor
for	IN	for
stroke	NN	stroke
and	CC	and
study	VV	study
the	DT	the
significance	NN	significance
of	IN	of
health-related	JJ	health-related
physical	JJ	physical
fitness	NN	fitness
testing	NN	testing
in	IN	in
stroke	NN	stroke
prevention	NN	prevention
among	IN	among
Chinese	JJ	Chinese
medical	JJ	medical
staff	NN	staff
members.A	NN	<unknown>
total	NN	total
of	IN	of
627	CD	@card@
subjects	NNS	subject
from	IN	from
Urumqi	NP	Urumqi
,	,	,
Xinjiang	NP	Xinjiang
,	,	,
China	NP	China
,	,	,
were	VBD	be
included	VVN	include
in	IN	in
the	DT	the
study	NN	study
and	CC	and
a	DT	a
survey	NN	survey
was	VBD	be
conducted	VVN	conduct
from	IN	from
1st	JJ	1st
January	NP	January
2016	CD	@card@
to	TO	to
1st	JJ	1st
February	NP	February
2016.	CD	@ord@
Stroke	NN	stroke
screening	NN	screening
and	CC	and
health-related	JJ	health-related
physical	JJ	physical
fitness	NN	fitness
testing	NN	testing
were	VBD	be
completed	VVN	complete
according	VVG	accord
to	TO	to
the	DT	the
standard	JJ	standard
protocol	NN	protocol
,	,	,
and	CC	and
the	DT	the
related	JJ	related
data	NNS	datum
were	VBD	be
analyzed.Based	JJ	<unknown>
on	IN	on
the	DT	the
screening	NN	screening
,	,	,
27.6	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
173	CD	@card@
)	)	)
of	IN	of
the	DT	the
subjects	NNS	subject
were	VBD	be
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
stroke	NN	stroke
.	SENT	.
The	DT	the
top	JJ	top
risk	NN	risk
factors	NNS	factor
for	IN	for
stroke	NN	stroke
in	IN	in
these	DT	these
subjects	NNS	subject
were	VBD	be
dyslipidemia	NNS	<unknown>
,	,	,
lack	NN	lack
of	IN	of
exercise	NN	exercise
or	CC	or
mild	JJ	mild
physical	JJ	physical
activity	NN	activity
,	,	,
being	VBG	be
overweight	JJ	overweight
or	CC	or
obese	JJ	obese
,	,	,
and	CC	and
high	JJ	high
blood	NN	blood
pressure	NN	pressure
.	SENT	.
Body	NN	body
weight	NN	weight
,	,	,
body	NN	body
mass	NN	mass
index	NN	index
,	,	,
body	NN	body
fat	NN	fat
,	,	,
visceral	JJ	visceral
fat	JJ	fat
area	NN	area
,	,	,
body	NN	body
fat	JJ	fat
percentage	NN	percentage
,	,	,
and	CC	and
basal	JJ	basal
metabolic	JJ	metabolic
rate	NN	rate
were	VBD	be
significantly	RB	significantly
higher	JJR	high
(	(	(
P	NN	P
&lt	NN	<unknown>
;	:	;
0.01	LS	@card@
)	)	)
in	IN	in
subjects	NNS	subject
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
stroke	NN	stroke
than	IN	than
in	IN	in
subjects	NNS	subject
who	WP	who
were	VBD	be
not	RB	not
at	IN	at
high	JJ	high
risk	NN	risk
.	SENT	.
Lung	NN	lung
capacity	NN	capacity
,	,	,
step	NN	step
index	NN	index
,	,	,
grip	NN	grip
test	NN	test
,	,	,
vertical	JJ	vertical
jump	NN	jump
,	,	,
and	CC	and
sit-up/push-up	NN	<unknown>
index	NN	index
were	VBD	be
significantly	RB	significantly
lower	JJR	low
(	(	(
P	NN	P
&lt	NN	<unknown>
;	:	;
0.01	LS	@card@
)	)	)
in	IN	in
subjects	NNS	subject
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
stroke	NN	stroke
than	IN	than
in	IN	in
subjects	NNS	subject
who	WP	who
were	VBD	be
not	RB	not
at	IN	at
high	JJ	high
risk.A	NN	<unknown>
large	JJ	large
proportion	NN	proportion
of	IN	of
China	NP	China
's	POS	's
on-the-job	NN	on-the-job
medical	JJ	medical
personnel	NNS	personnel
is	VBZ	be
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
stroke	NN	stroke
.	SENT	.
This	DT	this
may	MD	may
be	VB	be
related	VVN	relate
to	TO	to
the	DT	the
nature	NN	nature
of	IN	of
the	DT	the
profession	NN	profession
and	CC	and
warrants	NNS	warrant
more	JJR	more
attention	NN	attention
from	IN	from
the	DT	the
society	NN	society
.	SENT	.
The	DT	the
health-related	JJ	health-related
physical	JJ	physical
fitness	NN	fitness
measurement	NN	measurement
parameters	NNS	parameter
in	IN	in
subjects	NNS	subject
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
stroke	NN	stroke
were	VBD	be
significantly	RB	significantly
different	JJ	different
from	IN	from
those	DT	those
in	IN	in
subjects	NNS	subject
who	WP	who
were	VBD	be
not	RB	not
at	IN	at
high	JJ	high
risk	NN	risk
.	SENT	.
Screening	NN	screening
and	CC	and
health-related	JJ	health-related
physical	JJ	physical
fitness	NN	fitness
testing	NN	testing
in	IN	in
medical	JJ	medical
staff	NN	staff
members	NNS	member
may	MD	may
contribute	VV	contribute
to	TO	to
stroke	VV	stroke
prevention	NN	prevention
.	SENT	.
More	RBR	more
rigorous	JJ	rigorous
controlled	JJ	controlled
clinical	JJ	clinical
trials	NNS	trial
will	MD	will
be	VB	be
needed	VVN	need
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
T.	NP	T.
A	NP	A
Complicated	NP	<unknown>
Case	NP	Case
of	IN	of
Group	NP	Group
B	NP	B
Streptococcus	NP	<unknown>
Empyema	NP	<unknown>
Necessitans	NP	<unknown>
.	SENT	.
A.	NP	A.
Empyema	NP	<unknown>
necessitans	NNS	<unknown>
is	VBZ	be
a	DT	a
complication	NN	complication
of	IN	of
a	DT	a
pleural	JJ	pleural
space	NN	space
infection	NN	infection
that	WDT	that
dissects	VVZ	dissect
through	IN	through
the	DT	the
pleura	NNS	pleuron
into	IN	into
the	DT	the
soft	JJ	soft
tissues	NNS	tissue
of	IN	of
the	DT	the
chest	NN	chest
and	CC	and
skin	NN	skin
.	SENT	.
Due	JJ	due
to	TO	to
the	DT	the
widespread	JJ	widespread
availability	NN	availability
of	IN	of
antibiotics	NNS	antibiotic
,	,	,
empyema	NN	empyema
necessitans	NNS	<unknown>
is	VBZ	be
rare	JJ	rare
in	IN	in
modern	JJ	modern
medicine	NN	medicine
and	CC	and
is	VBZ	be
most	RBS	most
commonly	RB	commonly
caused	VVN	cause
by	IN	by
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
.	SENT	.
A	DT	a
38-year-old	JJ	38-year-old
immunocompetent	JJ	<unknown>
male	NN	male
presented	VVN	present
with	IN	with
left	JJ	left
shoulder	NN	shoulder
pain	NN	pain
and	CC	and
his	PP$	his
chest	NN	chest
radiograph	NN	radiograph
revealed	VVD	reveal
a	DT	a
mass	NN	mass
in	IN	in
the	DT	the
upper	JJ	upper
left	JJ	left
lung	NN	lung
and/or	CC	and/or
pleural	JJ	pleural
space	NN	space
.	SENT	.
He	PP	he
underwent	VVD	undergo
multiple	JJ	multiple
debridements	NNS	<unknown>
of	IN	of
the	DT	the
chest	NN	chest
wall	NN	wall
due	JJ	due
to	TO	to
a	DT	a
left	JJ	left
chest	NN	chest
wall	NN	wall
abscess	NN	abscess
and	CC	and
empyema	NN	empyema
necessitans	NNS	<unknown>
.	SENT	.
All	DT	all
operative	JJ	operative
samples	NNS	sample
were	VBD	be
positive	JJ	positive
for	IN	for
Streptococcus	NP	<unknown>
agalactiae	NNS	<unknown>
(	(	(
Group	NP	Group
B	NP	B
Streptococcus	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
patient	NN	patient
's	POS	's
clinical	JJ	clinical
course	NN	course
was	VBD	be
complicated	VVN	complicate
by	IN	by
septic	JJ	septic
arthritis	NN	arthritis
of	IN	of
the	DT	the
left	VVN	leave
sternoclavicular	JJ	<unknown>
joint	JJ	joint
and	CC	and
first	JJ	first
rib	NN	rib
,	,	,
vertebral	JJ	vertebral
osteomyelitis/discitis	NN	<unknown>
,	,	,
and	CC	and
pelvic	JJ	pelvic
abscesses	NNS	abscess
.	SENT	.
This	DT	this
case	NN	case
report	NN	report
illustrates	VVZ	illustrate
the	DT	the
pathogenic	JJ	pathogenic
process	NN	process
of	IN	of
empyema	NN	empyema
necessitans	NNS	<unknown>
and	CC	and
summarizes	VVZ	summarize
the	DT	the
clinical	JJ	clinical
management	NN	management
for	IN	for
practicing	VVG	practice
clinicians	NNS	clinician
.	SENT	.
It	PP	it
also	RB	also
documents	VVZ	document
the	DT	the
second	JJ	second
case	NN	case
of	IN	of
Streptococcus	NP	<unknown>
agalactiae-associated	JJ	<unknown>
empyema	NN	empyema
necessitans	NNS	<unknown>
,	,	,
to	TO	to
our	PP$	our
knowledge	NN	knowledge
,	,	,
with	IN	with
significantly	RB	significantly
greater	JJR	great
disease	NN	disease
extension	NN	extension
than	IN	than
the	DT	the
first	JJ	first
.	SENT	.
T.	NP	T.
Ocular	NP	<unknown>
tuberculosis	NN	tuberculosis
in	IN	in
Hospital	NP	Hospital
Universiti	NP	<unknown>
Sains	NP	<unknown>
Malaysia	NP	Malaysia
-	:	-
A	DT	a
case	NN	case
series	NN	series
.	SENT	.
A.	NP	A.
Ocular	NP	<unknown>
tuberculosis	NN	tuberculosis
(	(	(
TB	NN	TB
)	)	)
encompasses	VVZ	encompass
a	DT	a
broad	JJ	broad
spectrum	NN	spectrum
of	IN	of
clinical	JJ	clinical
manifestations	NNS	manifestation
affecting	VVG	affect
different	JJ	different
structures	NNS	structure
of	IN	of
the	DT	the
eye	NN	eye
.	SENT	.
It	PP	it
is	VBZ	be
caused	VVN	cause
by	IN	by
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
,	,	,
a	DT	a
great	JJ	great
ancient	JJ	ancient
organism	NN	organism
that	WDT	that
induces	VVZ	induce
various	JJ	various
types	NNS	type
of	IN	of
diseases	NNS	disease
and	CC	and
unfavorable	JJ	unfavorable
outcomes	NNS	outcome
if	IN	if
unrecognized	JJ	unrecognized
and	CC	and
not	RB	not
well	RB	well
treated.To	RB	<unknown>
report	VV	report
the	DT	the
clinical	JJ	clinical
profile	NN	profile
of	IN	of
34	CD	@card@
ocular	JJ	ocular
TB	NN	TB
cases	NNS	case
observed	VVD	observe
during	IN	during
6	CD	@card@
years	NNS	year
period	NN	period
in	IN	in
Hospital	NP	Hospital
Universiti	NP	<unknown>
Sains	NP	<unknown>
Malaysia	NP	Malaysia
(	(	(
HUSM).A	NP	<unknown>
retrospective	JJ	retrospective
review	NN	review
of	IN	of
medical	JJ	medical
records	NNS	record
from	IN	from
34	CD	@card@
patients	NNS	patient
diagnosed	VVN	diagnose
with	IN	with
ocular	JJ	ocular
TB	NN	TB
in	IN	in
HUSM	NP	<unknown>
from	IN	from
January	NP	January
2011	CD	@card@
until	IN	until
December	NP	December
2016.The	JJ	<unknown>
mean	NN	mean
age	NN	age
was	VBD	be
43	CD	@card@
±	SYM	±
14.6	CD	@card@
years	NNS	year
old	JJ	old
.	SENT	.
Both	DT	both
male	NN	male
and	CC	and
female	NN	female
affected	VVN	affect
in	IN	in
about	RB	about
1:1	CD	@card@
ratio	NN	ratio
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
subjects	NNS	subject
were	VBD	be
local	JJ	local
Malays	NNS	Malay
(	(	(
91.2	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Risk	NN	risk
factors	NNS	factor
included	VVD	include
previous	JJ	previous
contact	NN	contact
with	IN	with
pulmonary	JJ	pulmonary
TB	NN	TB
patients	NNS	patient
(	(	(
38.2	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
patients	NNS	patient
with	IN	with
underlying	VVG	underlie
diabetes	NN	diabetes
mellitus	NNS	<unknown>
(	(	(
26.5	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Most	JJS	most
patients	NNS	patient
showed	VVD	show
normal	JJ	normal
chest	NN	chest
radiography	NN	radiography
(	(	(
79.4	CD	@card@
%	NN	%
)	)	)
.	SENT	.
However	RB	however
they	PP	they
had	VHD	have
positive	JJ	positive
Mantoux	NP	<unknown>
test	NN	test
(	(	(
94.1	CD	@card@
%	NN	%
)	)	)
and	CC	and
raised	VVN	raise
erythrocyte	NN	erythrocyte
sedimentation	NN	sedimentation
rate	NN	rate
(	(	(
ESR	NP	<unknown>
)	)	)
value	NN	value
(	(	(
58.8	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Uveitis	NN	uveitis
was	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
ocular	JJ	ocular
manifestation	NN	manifestation
of	IN	of
ocular	JJ	ocular
TB	NN	TB
(	(	(
70.6	CD	@card@
%	NN	%
)	)	)
while	IN	while
the	DT	the
rare	JJ	rare
ocular	JJ	ocular
manifestations	NNS	manifestation
included	VVD	include
optic	JJ	optic
perineuritis	NN	perineuritis
and	CC	and
optic	JJ	optic
neuritis	NN	neuritis
,	,	,
orbital	JJ	orbital
apex	NN	apex
syndrome	NN	syndrome
,	,	,
orbital	JJ	orbital
cellulitis	NN	cellulitis
,	,	,
sclerokeratitis	NN	<unknown>
,	,	,
corneal	JJ	corneal
ulcer	NN	ulcer
and	CC	and
conjunctival	JJ	conjunctival
abscess	NN	abscess
.	SENT	.
All	DT	all
patients	NNS	patient
responded	VVD	respond
well	RB	well
to	TO	to
anti-TB	NN	<unknown>
treatment	NN	treatment
,	,	,
but	CC	but
visual	JJ	visual
outcome	NN	outcome
was	VBD	be
variable.This	NN	<unknown>
review	NN	review
shows	VVZ	show
the	DT	the
diverse	JJ	diverse
entity	NN	entity
of	IN	of
ocular	JJ	ocular
TB	NN	TB
spectrum	NN	spectrum
in	IN	in
an	DT	an
endemic	JJ	endemic
area	NN	area
.	SENT	.
Good	JJ	good
clinical	JJ	clinical
response	NN	response
to	TO	to
anti-tuberculous	JJ	<unknown>
therapy	NN	therapy
supported	VVD	support
the	DT	the
presumed	JJ	presumed
diagnosis	NN	diagnosis
of	IN	of
ocular	JJ	ocular
TB	NN	TB
in	IN	in
majority	NN	majority
of	IN	of
the	DT	the
cases	NNS	case
.	SENT	.
T.	NP	T.
Asymptomatic	NP	<unknown>
Giant	NP	Giant
Lipoma	NP	<unknown>
of	IN	of
the	DT	the
Right	NP	Right
Ventricular	NP	<unknown>
Outflow	NP	<unknown>
Tract	NP	<unknown>
:	:	:
A	DT	a
Case	NP	Case
Report	NP	Report
.	SENT	.
A.	NP	A.
Cardiac	NP	<unknown>
lipomas	NNS	lipoma
are	VBP	be
extremely	RB	extremely
rare	JJ	rare
tumors	NNS	tumor
of	IN	of
the	DT	the
heart	NN	heart
.	SENT	.
They	PP	they
are	VBP	be
usually	RB	usually
symptomatic	JJ	symptomatic
and	CC	and
rarely	RB	rarely
may	MD	may
be	VB	be
found	VVN	find
incidentally	RB	incidentally
in	IN	in
autopsies	NNS	autopsy
.	SENT	.
Here	RB	here
we	PP	we
describe	VVP	describe
a	DT	a
23-year-old	JJ	<unknown>
healthy	JJ	healthy
man	NN	man
,	,	,
in	IN	in
whose	WP$	whose
physical	JJ	physical
examination	NN	examination
for	IN	for
employment	NN	employment
a	DT	a
murmur	NN	murmur
was	VBD	be
found	VVN	find
incidentally	RB	incidentally
.	SENT	.
Transthoracic	JJ	<unknown>
and	CC	and
then	RB	then
transesophageal	JJ	<unknown>
echocardiographic	JJ	<unknown>
examination	NN	examination
showed	VVD	show
a	DT	a
4-cm	JJ	<unknown>
oval-shaped	JJ	<unknown>
mass	NN	mass
in	IN	in
the	DT	the
right	JJ	right
ventricular	JJ	ventricular
outflow	NN	outflow
tract	NN	tract
.	SENT	.
He	PP	he
underwent	VVD	undergo
elective	JJ	elective
surgery	NN	surgery
,	,	,
during	IN	during
which	WDT	which
the	DT	the
tumor	NN	tumor
was	VBD	be
removed	VVN	remove
under	IN	under
cardiopulmonary	JJ	cardiopulmonary
bypass	NN	bypass
and	CC	and
aortic-cross	NN	<unknown>
clamping	VVG	clamp
via	IN	via
right	JJ	right
atriotomy	NN	<unknown>
.	SENT	.
The	DT	the
postoperative	JJ	postoperative
course	NN	course
was	VBD	be
uneventful	JJ	uneventful
,	,	,
and	CC	and
the	DT	the
patient	NN	patient
was	VBD	be
in	IN	in
good	JJ	good
condition	NN	condition
at	IN	at
1	CD	@card@
year	NN	year
's	POS	's
follow-up	NN	follow-up
.	SENT	.
T.	NP	T.
Effect	NP	<unknown>
of	IN	of
smoking	NN	smoking
on	IN	on
acute	JJ	acute
phase	NN	phase
reactants	NNS	reactant
,	,	,
stress	NN	stress
hormone	NN	hormone
responses	NNS	response
and	CC	and
vitamin	NN	vitamin
C	NN	C
in	IN	in
pulmonary	JJ	pulmonary
tuberculosis	NN	tuberculosis
.	SENT	.
A.	NP	A.
Chronic	NP	<unknown>
inflammation	NN	inflammation
,	,	,
possibly	RB	possibly
exacerbated	VVN	exacerbate
by	IN	by
cigarette	NN	cigarette
smoking	NN	smoking
,	,	,
is	VBZ	be
considered	VVN	consider
to	TO	to
be	VB	be
the	DT	the
primary	JJ	primary
cause	NN	cause
of	IN	of
pulmonary	JJ	pulmonary
damage	NN	damage
in	IN	in
patients	NNS	patient
with	IN	with
tuberculosis	NN	tuberculosis
(	(	(
TB	NN	TB
)	)	)
.	SENT	.
However	RB	however
,	,	,
the	DT	the
mechanisms	NNS	mechanism
which	WDT	which
underpin	VVP	underpin
these	DT	these
harmful	JJ	harmful
inflammatory	JJ	inflammatory
responses	NNS	response
,	,	,
have	VHP	have
not	RB	not
been	VBN	be
well	RB	well
documented.The	JJ	<unknown>
current	JJ	current
study	NN	study
was	VBD	be
undertaken	VVN	undertake
to	TO	to
determine	VV	determine
possible	JJ	possible
associations	NNS	association
between	IN	between
systemic	JJ	systemic
biomarkers	NNS	<unknown>
of	IN	of
inflammation	NN	inflammation
(	(	(
acute	JJ	acute
phase	NN	phase
reactants	NNS	reactant
,	,	,
stress	NN	stress
hormones	NNS	hormone
,	,	,
leukocyte	NN	<unknown>
vitamin	NN	vitamin
C	NP	C
)	)	)
and	CC	and
smoking	NN	smoking
status	NN	status
in	IN	in
patients	NNS	patient
(	(	(
n=71	JJ	<unknown>
,	,	,
20	CD	@card@
smokers	NNS	smoker
)	)	)
with	IN	with
newly-diagnosed	JJ	<unknown>
pulmonary	JJ	pulmonary
TB	NN	TB
presenting	VVG	present
at	IN	at
a	DT	a
tertiary	JJ	tertiary
hospital	NN	hospital
,	,	,
Johannesburg	NP	Johannesburg
,	,	,
South	JJ	South
Africa.Plasma	NN	<unknown>
concentrations	NNS	concentration
of	IN	of
C-reactive	JJ	<unknown>
protein	NN	protein
(	(	(
CRP	NP	<unknown>
)	)	)
,	,	,
ferritin	NN	ferritin
,	,	,
cortisol	NN	cortisol
,	,	,
epinephrine	NN	epinephrine
,	,	,
norepinephrine	NN	norepinephrine
,	,	,
dopamine	NN	dopamine
and	CC	and
leukocyte	NN	<unknown>
vitamin	NN	vitamin
C	NP	C
were	VBD	be
measured	VVN	measure
using	VVG	use
a	DT	a
combination	NN	combination
of	IN	of
immunonephelometric	JJ	<unknown>
,	,	,
radioimmunoassay	JJ	<unknown>
,	,	,
immunochromatographic	JJ	<unknown>
and	CC	and
spectrophotometric	JJ	spectrophotometric
procedures	NNS	procedure
.	SENT	.
Demographic	JJ	demographic
,	,	,
clinical	JJ	clinical
and	CC	and
laboratory	NN	laboratory
data	NNS	datum
was	VBD	be
captured	VVN	capture
and	CC	and
analysed	VVN	analyse
by	IN	by
parametric	JJ	parametric
and	CC	and
non-parametric	JJ	<unknown>
analyses	NNS	analysis
where	WRB	where
appropriate.Smokers	NNS	<unknown>
were	VBD	be
predominantly	RB	predominantly
males	NNS	male
(	(	(
P&lt	NP	<unknown>
;	:	;
0.0001	LS	@card@
)	)	)
,	,	,
of	IN	of
older	JJR	old
age	NN	age
(	(	(
P&lt	NP	<unknown>
;	:	;
0.0003	LS	@card@
)	)	)
with	IN	with
a	DT	a
significantly	RB	significantly
lower	JJR	low
body	NN	body
mass	NN	mass
index	NN	index
(	(	(
P&lt	NP	<unknown>
;	:	;
0.03	LS	@card@
)	)	)
.	SENT	.
Plasma	NN	plasma
levels	NNS	level
of	IN	of
CRP	NP	<unknown>
,	,	,
ferritin	NN	ferritin
and	CC	and
dopamine	NN	dopamine
were	VBD	be
higher	JJR	high
in	IN	in
the	DT	the
group	NN	group
of	IN	of
smokers	NNS	smoker
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
lower	JJR	low
levels	NNS	level
of	IN	of
epinephrine	NN	epinephrine
,	,	,
and	CC	and
leukocyte	NN	<unknown>
vitamin	NN	vitamin
C	NP	C
,	,	,
with	IN	with
CRP	NP	<unknown>
and	CC	and
vitamin	NN	vitamin
C	NN	C
attaining	VVG	attain
statistical	JJ	statistical
significance	NN	significance
(	(	(
P&lt	NP	<unknown>
;	:	;
0.04	CD	@card@
and	CC	and
P&lt	NP	<unknown>
;	:	;
0.02	CD	@card@
respectively	RB	respectively
)	)	)
.	SENT	.
Those	DT	those
of	IN	of
cortisol	NN	cortisol
and	CC	and
norepinephrine	NN	norepinephrine
were	VBD	be
comparable	JJ	comparable
to	TO	to
those	DT	those
of	IN	of
non-smokers	NNS	non-smoker
,	,	,
as	RB	as
were	VBD	be
radiographic	JJ	radiographic
changes	NNS	change
and	CC	and
clinical	JJ	clinical
indices	NN	indices
of	IN	of
disease	NN	disease
activity.Cigarette	NN	<unknown>
smoking	NN	smoking
is	VBZ	be
associated	VVN	associate
with	IN	with
an	DT	an
exaggerated	JJ	exaggerated
systemic	JJ	systemic
inflammatory	JJ	inflammatory
response	NN	response
in	IN	in
pulmonary	JJ	pulmonary
TB	NN	TB
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
decreased	VVN	decrease
concentrations	NNS	concentration
of	IN	of
leukocyte	NN	<unknown>
vitamin	NN	vitamin
C.	NP	C.
Although	IN	although
no	DT	no
significant	JJ	significant
associations	NNS	association
with	IN	with
radiographic	JJ	radiographic
changes	NNS	change
and	CC	and
most	RBS	most
clinical	JJ	clinical
indices	NN	indices
of	IN	of
disease	NN	disease
activity	NN	activity
were	VBD	be
evident	JJ	evident
on	IN	on
presentation	NN	presentation
,	,	,
these	DT	these
pro-inflammatory	JJ	<unknown>
interactions	NNS	interaction
may	MD	may
have	VH	have
prognostic	JJ	prognostic
significance	NN	significance
.	SENT	.
T.	NP	T.
Oxycodone	NP	<unknown>
Resistance	NP	Resistance
Due	NP	Due
to	TO	to
Rifampin	NP	<unknown>
Use	NP	Use
in	IN	in
an	DT	an
Osteosarcoma	NP	<unknown>
Patient	NP	Patient
with	IN	with
Tuberculosis	NN	tuberculosis
.	SENT	.
A.	NP	A.
BACKGROUND	NP	<unknown>
Oxycodone	NP	<unknown>
is	VBZ	be
a	DT	a
semisynthetic	JJ	<unknown>
opioid	JJ	<unknown>
receptor	NN	receptor
agonist	NN	agonist
,	,	,
and	CC	and
is	VBZ	be
frequently	RB	frequently
used	VVN	use
for	IN	for
pain	NN	pain
control	NN	control
in	IN	in
patients	NNS	patient
with	IN	with
cancer	NN	cancer
.	SENT	.
Most	JJS	most
oxycodone	NN	<unknown>
is	VBZ	be
metabolized	VVN	metabolize
by	IN	by
N-demethylation	NN	<unknown>
to	TO	to
noroxycodone	NN	<unknown>
by	IN	by
CYP3A	NP	<unknown>
.	SENT	.
Rifampin	NP	<unknown>
is	VBZ	be
a	DT	a
strong	JJ	strong
inducer	NN	inducer
of	IN	of
several	JJ	several
drug-metabolizing	VVG	<unknown>
enzymes	NNS	enzyme
,	,	,
including	VVG	include
CYP3A	NP	<unknown>
.	SENT	.
Hence	RB	hence
,	,	,
rifampin-induced	JJ	<unknown>
CYP3A	NP	<unknown>
activity	NN	activity
may	MD	may
decrease	VV	decrease
the	DT	the
effect	NN	effect
of	IN	of
oxycodone	NN	<unknown>
.	SENT	.
CASE	NN	case
REPORT	NP	Report
Osteosarcoma	NP	<unknown>
is	VBZ	be
a	DT	a
highly	RB	highly
aggressive	JJ	aggressive
primary	JJ	primary
bone	NN	bone
tumor	NN	tumor
of	IN	of
childhood	NN	childhood
and	CC	and
adolescence	NN	adolescence
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
report	VVP	report
a	DT	a
30-year-old	JJ	30-year-old
male	NN	male
with	IN	with
osteosarcoma	NN	<unknown>
of	IN	of
the	DT	the
femur	NN	femur
with	IN	with
lung	NN	lung
metastases	NNS	metastasis
in	IN	in
the	DT	the
upper	JJ	upper
lobe	NN	lobe
.	SENT	.
The	DT	the
lung	NN	lung
also	RB	also
contained	VVD	contain
small	JJ	small
,	,	,
scattered	JJ	scattered
nodular	JJ	nodular
lesions	NNS	lesion
that	WDT	that
were	VBD	be
identified	VVN	identify
as	IN	as
tuberculosis	NN	tuberculosis
.	SENT	.
Multi-drug	NN	<unknown>
therapy	NN	therapy
,	,	,
including	VVG	include
rifampin	NN	<unknown>
,	,	,
was	VBD	be
administered	VVN	administer
.	SENT	.
The	DT	the
upper-lobe	NN	<unknown>
metastatic	JJ	metastatic
lesion	NN	lesion
extended	VVN	extend
to	TO	to
the	DT	the
brachial	JJ	brachial
plexus	NN	plexus
and	CC	and
caused	VVD	cause
severe	JJ	severe
pain	NN	pain
.	SENT	.
Over	IN	over
1000	CD	@card@
mg	NN	mg
per	IN	per
day	NN	day
of	IN	of
oxycodone	NN	<unknown>
was	VBD	be
ineffective	JJ	ineffective
for	IN	for
pain	NN	pain
control	NN	control
.	SENT	.
However	RB	however
,	,	,
morphine	NN	morphine
was	VBD	be
able	JJ	able
to	TO	to
control	VV	control
his	PP$	his
pain	NN	pain
at	IN	at
about	RB	about
one-third	JJ	one-third
the	DT	the
equivalent	JJ	equivalent
dose	NN	dose
.	SENT	.
CONCLUSIONS	NNS	conclusion
Our	JJ	<unknown>
patient	NN	patient
demonstrated	VVD	demonstrate
oxycodone	NN	<unknown>
resistance	NN	resistance
due	JJ	due
to	TO	to
rifampin	NN	<unknown>
.	SENT	.
Chemotherapy	NN	chemotherapy
may	MD	may
have	VH	have
compromised	VVN	compromise
the	DT	the
patient	NN	patient
's	POS	's
immune	JJ	immune
system	NN	system
,	,	,
thus	RB	thus
theoretically	RB	theoretically
increasing	VVG	increase
the	DT	the
risk	NN	risk
of	IN	of
tuberculosis	NN	tuberculosis
.	SENT	.
Recognition	NN	recognition
of	IN	of
the	DT	the
interactions	NNS	interaction
between	IN	between
rifampin	NN	<unknown>
and	CC	and
oxycodone	NN	<unknown>
is	VBZ	be
important	JJ	important
in	IN	in
this	DT	this
and	CC	and
other	JJ	other
cancers	NNS	cancer
.	SENT	.
Notably	RB	notably
,	,	,
for	IN	for
patients	NNS	patient
using	VVG	use
high	JJ	high
doses	NNS	dose
of	IN	of
oxycodone	NN	<unknown>
to	TO	to
manage	VV	manage
severe	JJ	severe
pain	NN	pain
,	,	,
stopping	VVG	stop
rifampin	NN	<unknown>
may	MD	may
lead	VV	lead
to	TO	to
oxycodone	NN	<unknown>
overdose	NN	overdose
.	SENT	.
T.	NP	T.
Classification	NP	Classification
of	IN	of
voluntary	JJ	voluntary
coughs	NNS	cough
applied	VVN	apply
to	TO	to
the	DT	the
screening	NN	screening
of	IN	of
respiratory	JJ	respiratory
disease	NN	disease
.	SENT	.
A.	NP	A.
Pulmonary	NP	<unknown>
and	CC	and
respiratory	JJ	respiratory
diseases	NNS	disease
(	(	(
e.g.	FW	e.g.
asthma	NN	asthma
,	,	,
COPD	NP	<unknown>
,	,	,
allergies	NNS	allergy
,	,	,
pneumonia	NN	pneumonia
,	,	,
tuberculosis	NN	tuberculosis
,	,	,
etc.	FW	etc.
)	)	)
represent	VV	represent
a	DT	a
large	JJ	large
proportion	NN	proportion
of	IN	of
the	DT	the
global	JJ	global
disease	NN	disease
burden	NN	burden
,	,	,
mortality	NN	mortality
,	,	,
and	CC	and
disability	NN	disability
.	SENT	.
In	IN	in
this	DT	this
context	NN	context
of	IN	of
creating	VVG	create
automated	JJ	automated
diagnostic	JJ	diagnostic
tools	NNS	tool
,	,	,
we	PP	we
explore	VVP	explore
how	WRB	how
the	DT	the
analysis	NN	analysis
of	IN	of
voluntary	JJ	voluntary
cough	NN	cough
sounds	NNS	sound
may	MD	may
be	VB	be
used	VVN	use
to	TO	to
screen	VV	screen
for	IN	for
pulmonary	JJ	pulmonary
disease	NN	disease
.	SENT	.
As	IN	as
a	DT	a
clinical	JJ	clinical
study	NN	study
,	,	,
voluntary	JJ	voluntary
coughs	NNS	cough
were	VBD	be
recorded	VVN	record
using	VVG	use
a	DT	a
custom	JJ	custom
mobile	JJ	mobile
phone	NN	phone
stethoscope	NN	stethoscope
from	IN	from
54	CD	@card@
patients	NNS	patient
,	,	,
of	IN	of
which	WDT	which
7	CD	@card@
had	VHD	have
COPD	NN	<unknown>
,	,	,
15	CD	@card@
had	VHD	have
asthma	NN	asthma
,	,	,
11	CD	@card@
had	VHD	have
allergic	JJ	allergic
rhinitis	NN	rhinitis
,	,	,
17	CD	@card@
had	VHD	have
both	DT	both
asthma	NN	asthma
and	CC	and
allergic	JJ	allergic
rhinitis	NN	rhinitis
,	,	,
and	CC	and
four	CD	four
had	VHD	have
both	DT	both
COPD	NN	<unknown>
and	CC	and
allergic	JJ	allergic
rhinitis	NN	rhinitis
.	SENT	.
Data	NNS	datum
were	VBD	be
also	RB	also
collected	VVN	collect
from	IN	from
33	CD	@card@
healthy	JJ	healthy
subjects	NNS	subject
.	SENT	.
These	DT	these
patients	NNS	patient
also	RB	also
received	VVD	receive
full	JJ	full
auscultation	NN	auscultation
at	IN	at
11	CD	@card@
sites	NNS	site
,	,	,
given	VVN	give
a	DT	a
clinical	JJ	clinical
questionnaire	NN	questionnaire
,	,	,
and	CC	and
underwent	VVD	undergo
full	JJ	full
pulmonary	JJ	pulmonary
function	NN	function
testing	NN	testing
(	(	(
spirometer	NN	spirometer
,	,	,
body	NN	body
plethysmograph	NN	plethysmograph
,	,	,
DLCO	NP	<unknown>
)	)	)
which	WDT	which
culminated	VVD	culminate
in	IN	in
a	DT	a
diagnosis	NN	diagnosis
provided	VVN	provide
by	IN	by
an	DT	an
experienced	JJ	experienced
pulmonologist	NN	<unknown>
.	SENT	.
From	IN	from
machine	NN	machine
learning	VVG	learn
analysis	NN	analysis
of	IN	of
these	DT	these
data	NNS	datum
,	,	,
we	PP	we
show	VVP	show
that	IN/that	that
it	PP	it
is	VBZ	be
possible	JJ	possible
to	TO	to
achieve	VV	achieve
good	JJ	good
classification	NN	classification
of	IN	of
cough	NN	cough
sounds	NNS	sound
in	IN	in
terms	NNS	term
of	IN	of
Wet	NP	<unknown>
vs	NP	vs
Dry	NP	Dry
,	,	,
yielding	VVG	yield
an	DT	an
ROC	NP	<unknown>
curve	NN	curve
with	IN	with
AUC	NP	<unknown>
of	IN	of
0.94	CD	@card@
,	,	,
and	CC	and
show	VVP	show
that	IN/that	that
voluntary	JJ	voluntary
coughs	NNS	cough
can	MD	can
serve	VV	serve
as	IN	as
an	DT	an
effective	JJ	effective
test	NN	test
for	IN	for
determining	VVG	determine
Healthy	JJ	healthy
vs	NP	vs
Unhealthy	NP	<unknown>
(	(	(
sensitivity=35.7	JJ	<unknown>
%	NN	%
specificity=100	NN	<unknown>
%	NN	%
)	)	)
.	SENT	.
We	PP	we
also	RB	also
show	VVP	show
that	IN/that	that
the	DT	the
use	NN	use
of	IN	of
cough	NN	cough
sounds	NNS	sound
can	MD	can
enhance	VV	enhance
the	DT	the
performance	NN	performance
of	IN	of
other	JJ	other
diagnostic	JJ	diagnostic
tools	NNS	tool
such	JJ	such
as	IN	as
a	DT	a
patient	JJ	patient
questionnaire	NN	questionnaire
and	CC	and
peak	NN	peak
flow	NN	flow
meter	NN	meter
;	:	;
however	RB	however
voluntary	JJ	voluntary
coughs	NNS	cough
alone	RB	alone
provide	VVP	provide
relatively	RB	relatively
little	JJ	little
value	NN	value
in	IN	in
determining	VVG	determine
specific	JJ	specific
disease	NN	disease
diagnosis	NN	diagnosis
.	SENT	.
T.	NP	T.
Genome-wide	JJ	<unknown>
interaction	NN	interaction
study	NN	study
of	IN	of
smoking	NN	smoking
behavior	NN	behavior
and	CC	and
non-small	NN	<unknown>
cell	NN	cell
lung	NN	lung
cancer	NN	cancer
risk	NN	risk
in	IN	in
Caucasian	JJ	Caucasian
population	NN	population
.	SENT	.
A.	NP	A.
Non-small	NP	<unknown>
cell	NN	cell
lung	NN	lung
cancer	NN	cancer
(	(	(
NSCLC	NP	<unknown>
)	)	)
is	VBZ	be
the	DT	the
most	RBS	most
common	JJ	common
type	NN	type
of	IN	of
lung	NN	lung
cancer	NN	cancer
.	SENT	.
Both	DT	both
environmental	JJ	environmental
and	CC	and
genetic	JJ	genetic
risk	NN	risk
factors	NNS	factor
contribute	VVP	contribute
to	TO	to
lung	NN	lung
carcinogenesis	NN	<unknown>
.	SENT	.
We	PP	we
conducted	VVD	conduct
a	DT	a
genome-wide	JJ	<unknown>
interaction	NN	interaction
analysis	NN	analysis
between	IN	between
SNPs	NP	<unknown>
and	CC	and
smoking	NN	smoking
status	NN	status
(	(	(
never	RB	never
vs	NP	vs
ever	RB	ever
smokers	NNS	smoker
)	)	)
in	IN	in
a	DT	a
European-descent	JJ	<unknown>
population	NN	population
.	SENT	.
We	PP	we
adopted	VVD	adopt
a	DT	a
two-step	JJ	two-step
analysis	NN	analysis
strategy	NN	strategy
in	IN	in
the	DT	the
discovery	NN	discovery
stage	NN	stage
:	:	:
we	PP	we
first	RB	first
conducted	VVD	conduct
a	DT	a
case-only	JJ	<unknown>
interaction	NN	interaction
analysis	NN	analysis
to	TO	to
assess	VV	assess
the	DT	the
relationship	NN	relationship
between	IN	between
SNPs	NP	<unknown>
and	CC	and
smoking	NN	smoking
behavior	NN	behavior
using	VVG	use
13,336	CD	@card@
NSCLC	NP	<unknown>
cases	NNS	case
.	SENT	.
Candidate	NN	candidate
SNPs	NNS	<unknown>
with	IN	with
p-value	NN	<unknown>
less	JJR	less
than	IN	than
0.001	CD	@card@
were	VBD	be
further	RBR	further
analyzed	VVN	analyze
using	VVG	use
a	DT	a
standard	JJ	standard
case-control	NN	<unknown>
interaction	NN	interaction
analysis	NN	analysis
including	VVG	include
13970	CD	@card@
controls	NNS	control
.	SENT	.
The	DT	the
significant	JJ	significant
SNPs	NNS	<unknown>
with	IN	with
p-value	NN	<unknown>
less	RBR	less
than	IN	than
3.5x10-5	JJ	<unknown>
(	(	(
correcting	VVG	correct
for	IN	for
multiple	JJ	multiple
tests	NNS	test
)	)	)
from	IN	from
the	DT	the
case-control	NN	<unknown>
analysis	NN	analysis
in	IN	in
the	DT	the
discovery	NN	discovery
stage	NN	stage
were	VBD	be
further	RBR	further
validated	VVN	validate
using	VVG	use
an	DT	an
independent	JJ	independent
replication	NN	replication
dataset	NN	<unknown>
comprising	VVG	comprise
5377	CD	@card@
controls	NNS	control
and	CC	and
3054	CD	@card@
NSCLC	NP	<unknown>
cases	NNS	case
.	SENT	.
We	PP	we
further	RBR	further
stratified	VVD	stratify
the	DT	the
analysis	NN	analysis
by	IN	by
histological	JJ	histological
subtypes	NNS	subtype
.	SENT	.
Two	CD	two
novel	NN	novel
SNPs	NP	<unknown>
,	,	,
rs6441286	NN	<unknown>
and	CC	and
rs17723637	JJ	<unknown>
,	,	,
were	VBD	be
identified	VVN	identify
for	IN	for
overall	JJ	overall
lung	NN	lung
cancer	NN	cancer
risk	NN	risk
.	SENT	.
The	DT	the
interaction	NN	interaction
odds	NNS	odd
ratio	NN	ratio
and	CC	and
meta-analysis	NN	<unknown>
p-value	NN	<unknown>
for	IN	for
these	DT	these
two	CD	two
SNPs	NNS	<unknown>
were	VBD	be
1.24	CD	@card@
with	IN	with
6.96x10-7	JJ	<unknown>
and	CC	and
1.37	CD	@card@
with	IN	with
3.49x10-7	JJ	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
Additionally	RB	additionally
,	,	,
interaction	NN	interaction
of	IN	of
smoking	NN	smoking
with	IN	with
rs4751674	NN	<unknown>
was	VBD	be
identified	VVN	identify
in	IN	in
squamous	JJ	squamous
cell	NN	cell
lung	NN	lung
carcinoma	NN	carcinoma
with	IN	with
an	DT	an
odds	NNS	odd
ratio	NN	ratio
of	IN	of
0.58	CD	@card@
and	CC	and
p-value	NN	<unknown>
of	IN	of
8.12x10-7	JJ	<unknown>
.	SENT	.
This	DT	this
study	NN	study
is	VBZ	be
by	IN	by
far	RB	far
the	DT	the
largest	JJS	large
genome-wide	JJ	<unknown>
SNP-smoking	NP	<unknown>
interaction	NN	interaction
analysis	NN	analysis
reported	VVD	report
for	IN	for
lung	NN	lung
cancer	NN	cancer
.	SENT	.
The	DT	the
three	CD	three
identified	VVN	identify
novel	NN	novel
SNPs	NNS	<unknown>
provide	VVP	provide
potential	JJ	potential
candidate	NN	candidate
biomarkers	NNS	<unknown>
for	IN	for
lung	NN	lung
cancer	NN	cancer
risk	NN	risk
screening	NN	screening
and	CC	and
intervention	NN	intervention
.	SENT	.
The	DT	the
results	NNS	result
from	IN	from
our	PP$	our
study	NN	study
reinforce	VV	reinforce
that	IN/that	that
gene-smoking	NN	<unknown>
interactions	NNS	interaction
play	VVP	play
important	JJ	important
roles	NNS	role
in	IN	in
the	DT	the
etiology	NN	etiology
of	IN	of
lung	NN	lung
cancer	NN	cancer
and	CC	and
account	NN	account
for	IN	for
part	NN	part
of	IN	of
the	DT	the
missing	JJ	missing
heritability	NN	heritability
of	IN	of
this	DT	this
disease	NN	disease
.	SENT	.
T.	NP	T.
Effect	NP	<unknown>
of	IN	of
glycemic	JJ	<unknown>
control	NN	control
and	CC	and
type	NN	type
of	IN	of
diabetes	NN	diabetes
treatment	NN	treatment
on	IN	on
unsuccessful	JJ	unsuccessful
TB	NN	TB
treatment	NN	treatment
outcomes	NNS	outcome
among	IN	among
people	NNS	people
with	IN	with
TB-Diabetes	NP	<unknown>
:	:	:
A	DT	a
systematic	JJ	systematic
review	NN	review
.	SENT	.
A.	NP	A.
Stringent	NP	<unknown>
glycemic	JJ	<unknown>
control	NN	control
by	IN	by
using	VVG	use
insulin	NN	insulin
as	IN	as
a	DT	a
replacement	NN	replacement
or	CC	or
in	IN	in
addition	NN	addition
to	TO	to
oral	JJ	oral
hypoglycemic	JJ	hypoglycemic
agents	NNS	agent
(	(	(
OHAs	NP	<unknown>
)	)	)
has	VHZ	have
been	VBN	be
recommended	VVN	recommend
for	IN	for
people	NNS	people
with	IN	with
tuberculosis	NN	tuberculosis
and	CC	and
diabetes	NN	diabetes
mellitus	NN	<unknown>
(	(	(
TB-DM	NP	<unknown>
)	)	)
.	SENT	.
This	DT	this
systematic	JJ	systematic
review	NN	review
(	(	(
PROSPERO	NP	Prospero
2016:CRD42016039101	JJ	<unknown>
)	)	)
analyses	NNS	analysis
whether	IN	whether
this	DT	this
improves	VVZ	improve
TB	NN	TB
treatment	NN	treatment
outcomes.Among	NN	<unknown>
people	NNS	people
with	IN	with
drug-susceptible	JJ	<unknown>
TB	NN	TB
and	CC	and
DM	NP	DM
on	IN	on
anti-TB	NN	<unknown>
treatment	NN	treatment
,	,	,
to	TO	to
determine	VV	determine
the	DT	the
effect	NN	effect
of	IN	of
i	NP	i
)	)	)
glycemic	JJ	<unknown>
control	NN	control
(	(	(
stringent	JJ	stringent
or	CC	or
less	RBR	less
stringent	JJ	stringent
)	)	)
compared	VVN	compare
to	TO	to
poor	JJ	poor
glycemic	JJ	<unknown>
control	NN	control
and	CC	and
ii	NN	<unknown>
)	)	)
insulin	NN	insulin
(	(	(
only	RB	only
or	CC	or
with	IN	with
OHAs	NNS	<unknown>
)	)	)
compared	VVN	compare
to	TO	to
'OHAs	NP	<unknown>
only'	NP	<unknown>
on	IN	on
unsuccessful	JJ	unsuccessful
TB	NN	TB
treatment	NN	treatment
outcome(s	NNS	<unknown>
)	)	)
.	SENT	.
We	PP	we
looked	VVD	look
for	IN	for
unfavourable	JJ	unfavourable
TB	NN	TB
treatment	NN	treatment
outcomes	NNS	outcome
at	IN	at
the	DT	the
end	NN	end
of	IN	of
intensive	JJ	intensive
phase	NN	phase
and/or	CC	and/or
end	NN	end
of	IN	of
TB	NN	TB
treatment	NN	treatment
(	(	(
minimum	NN	minimum
six	CD	six
months	NNS	month
and	CC	and
maximum	JJ	maximum
12	CD	@card@
months	NNS	month
follow	VVP	follow
up	RP	up
)	)	)
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
were	VBD	be
development	NN	development
of	IN	of
MDR-TB	NP	<unknown>
during	IN	during
the	DT	the
course	NN	course
of	IN	of
treatment	NN	treatment
,	,	,
recurrence	NN	recurrence
after	IN	after
6	CD	@card@
months	NNS	month
and/or	CC	and/or
after	IN	after
1	CD	@card@
year	NN	year
post	NN	post
successful	JJ	successful
treatment	NN	treatment
completion	NN	completion
and	CC	and
development	NN	development
of	IN	of
adverse	JJ	adverse
events	NNS	event
related	VVN	relate
to	TO	to
glucose	NN	glucose
lowering	VVG	lower
treatment	NN	treatment
(	(	(
including	VVG	include
hypoglycemic	JJ	hypoglycemic
episodes).All	NN	<unknown>
interventional	JJ	interventional
studies	NNS	study
(	(	(
with	IN	with
comparison	NN	comparison
arm	NN	arm
)	)	)
and	CC	and
cohort	NN	cohort
studies	NNS	study
on	IN	on
people	NNS	people
with	IN	with
TB-DM	NP	<unknown>
on	IN	on
anti-TB	NN	<unknown>
treatment	NN	treatment
reporting	VVG	report
glycemic	JJ	<unknown>
control	NN	control
,	,	,
DM	NP	DM
treatment	NN	treatment
details	NNS	detail
and	CC	and
TB	NN	TB
treatment	NN	treatment
outcomes	NNS	outcome
were	VBD	be
eligible	JJ	eligible
.	SENT	.
We	PP	we
searched	VVD	search
electronic	JJ	electronic
databases	NNS	database
(	(	(
EMBASE	NP	<unknown>
,	,	,
PubMed	NP	<unknown>
,	,	,
Google	NP	<unknown>
Scholar	NP	<unknown>
)	)	)
and	CC	and
grey	JJ	grey
literature	NN	literature
between	IN	between
1996	CD	@card@
and	CC	and
April	NP	April
2017.	CD	@ord@
Screening	NP	<unknown>
,	,	,
data	NN	data
extraction	NN	extraction
and	CC	and
risk	NN	risk
of	IN	of
bias	NN	bias
assessment	NN	assessment
were	VBD	be
done	VVN	do
independently	RB	independently
by	IN	by
two	CD	two
investigators	NNS	investigator
and	CC	and
recourse	NN	recourse
to	TO	to
a	DT	a
third	JJ	third
investigator	NN	investigator
,	,	,
for	IN	for
resolution	NN	resolution
of	IN	of
differences.After	NN	<unknown>
removal	NN	removal
of	IN	of
duplicates	NNS	duplicate
from	IN	from
2326	CD	@card@
identified	VVN	identify
articles	NNS	article
,	,	,
2054	CD	@card@
underwent	VVD	undergo
title	NN	title
and	CC	and
abstract	JJ	abstract
screening	NN	screening
.	SENT	.
Following	VVG	follow
full	JJ	full
text	NN	text
screening	NN	screening
of	IN	of
56	CD	@card@
articles	NNS	article
,	,	,
nine	CD	nine
cohort	NN	cohort
studies	NNS	study
were	VBD	be
included	VVN	include
.	SENT	.
Considering	VVG	consider
high	JJ	high
methodological	JJ	methodological
and	CC	and
clinical	JJ	clinical
heterogeneity	NN	heterogeneity
,	,	,
we	PP	we
decided	VVD	decide
to	TO	to
report	VV	report
the	DT	the
results	NNS	result
qualitatively	RB	qualitatively
and	CC	and
not	RB	not
perform	VV	perform
a	DT	a
meta-analysis	NN	<unknown>
.	SENT	.
Eight	CD	eight
studies	NNS	study
dealt	VVN	deal
with	IN	with
glycemic	JJ	<unknown>
control	NN	control
,	,	,
of	IN	of
which	WDT	which
only	JJ	only
two	CD	two
were	VBD	be
free	JJ	free
of	IN	of
the	DT	the
risk	NN	risk
of	IN	of
bias	NN	bias
(	(	(
with	IN	with
confounder-adjusted	JJ	<unknown>
measures	NNS	measure
of	IN	of
effect	NN	effect
)	)	)
.	SENT	.
An	DT	an
Indian	JJ	Indian
study	NN	study
reported	VVD	report
30	CD	@card@
%	NN	%
fewer	JJR	few
unsuccessful	JJ	unsuccessful
treatment	NN	treatment
outcomes	NNS	outcome
(	(	(
aOR	NN	<unknown>
(	(	(
0.95	CD	@card@
CI	NP	<unknown>
)	)	)
:	:	:
0.72	CD	@card@
(	(	(
0.64-0.81	CD	@card@
)	)	)
)	)	)
and	CC	and
2.8	CD	@card@
times	NNS	time
higher	JJR	high
odds	NNS	odd
of	IN	of
'no	NP	<unknown>
recurrence'	NP	<unknown>
(	(	(
aOR	NN	<unknown>
(	(	(
0.95	CD	@card@
CI	NP	<unknown>
)	)	)
:	:	:
2.83	CD	@card@
(	(	(
2.60-2.92	CD	@card@
)	)	)
)	)	)
among	IN	among
patients	NNS	patient
with	IN	with
optimal	JJ	optimal
glycemic	JJ	<unknown>
control	NN	control
at	IN	at
baseline	NN	baseline
.	SENT	.
A	DT	a
Peruvian	JJ	Peruvian
study	NN	study
reported	VVD	report
faster	JJR	fast
culture	NN	culture
conversion	NN	conversion
among	IN	among
those	DT	those
with	IN	with
glycemic	JJ	<unknown>
control	NN	control
(	(	(
aHR	NN	<unknown>
(	(	(
0.95	CD	@card@
CI	NP	<unknown>
)	)	)
:	:	:
2.2	CD	@card@
(	(	(
1.1,4	CD	@card@
)	)	)
)	)	)
.	SENT	.
Two	CD	two
poor	JJ	poor
quality	NN	quality
studies	NNS	study
reported	VVD	report
the	DT	the
effect	NN	effect
of	IN	of
insulin	NN	insulin
on	IN	on
TB	NN	TB
treatment	NN	treatment
outcomes.We	NP	<unknown>
identified	VVD	identify
few	JJ	few
studies	NNS	study
that	WDT	that
were	VBD	be
free	JJ	free
of	IN	of
the	DT	the
risk	NN	risk
of	IN	of
bias	NN	bias
.	SENT	.
There	EX	there
were	VBD	be
limited	JJ	limited
data	NNS	datum
and	CC	and
inconsistent	JJ	inconsistent
findings	NNS	finding
among	IN	among
available	JJ	available
studies	NNS	study
.	SENT	.
We	PP	we
recommend	VVP	recommend
robustly	RB	robustly
designed	VVN	design
and	CC	and
analyzed	VVN	analyze
studies	NNS	study
including	VVG	include
randomized	VVN	randomize
controlled	JJ	controlled
trials	NNS	trial
on	IN	on
the	DT	the
effect	NN	effect
of	IN	of
glucose	NN	glucose
lowering	VVG	lower
treatment	NN	treatment
options	NNS	option
on	IN	on
TB	NN	TB
treatment	NN	treatment
outcomes	NNS	outcome
.	SENT	.
T.	NP	T.
Nocardia	NP	<unknown>
beijingensis	NN	<unknown>
pericarditis	NN	pericarditis
presenting	VVG	present
with	IN	with
cardiac	JJ	cardiac
tamponade	NN	<unknown>
:	:	:
A	DT	a
case	NN	case
report	NN	report
.	SENT	.
A.	NP	A.
We	PP	we
report	VVP	report
the	DT	the
first	JJ	first
case	NN	case
of	IN	of
Nocardia	NP	<unknown>
beijingensis	NN	<unknown>
pericarditis	NN	pericarditis
in	IN	in
a	DT	a
32-year-old	JJ	<unknown>
HIV-infected	JJ	HIV-infected
patient	NN	patient
.	SENT	.
He	PP	he
presented	VVD	present
with	IN	with
cardiac	JJ	cardiac
tamponade	NN	<unknown>
after	IN	after
failing	VVG	fail
to	TO	to
respond	VV	respond
to	TO	to
treatment	NN	treatment
for	IN	for
smear-negative	JJ	<unknown>
pulmonary	JJ	pulmonary
and	CC	and
pericardial	JJ	pericardial
tuberculosis	NN	tuberculosis
(	(	(
TB	NN	TB
)	)	)
.	SENT	.
The	DT	the
pericardial	JJ	pericardial
fluid	NN	fluid
was	VBD	be
examined	VVN	examine
several	JJ	several
times	NNS	time
before	IN	before
it	PP	it
eventually	RB	eventually
revealed	VVD	reveal
filamentous	JJ	filamentous
branching	VVG	branch
organisms	NNS	organism
in	IN	in
Gram	NP	Gram
and	CC	and
modified	JJ	modified
acid-fast	JJ	acid-fast
bacilli	NNS	bacillus
stain	VVP	stain
.	SENT	.
The	DT	the
culture	NN	culture
grew	VVD	grow
Nocardia	NP	<unknown>
spp	NP	<unknown>
.	SENT	.
and	CC	and
was	VBD	be
identified	VVN	identify
by	IN	by
16s	NP	<unknown>
rRNA	NP	<unknown>
sequencing	NP	sequencing
as	IN	as
N.	NP	N.
beijingensis	NN	<unknown>
.	SENT	.
Eight	CD	eight
previously	RB	previously
reported	VVD	report
cases	NNS	case
of	IN	of
Nocardia	NP	<unknown>
pericarditis	NN	pericarditis
in	IN	in
HIV-infected	JJ	HIV-infected
patients	NNS	patient
were	VBD	be
caused	VVN	cause
by	IN	by
Nocardia	NP	<unknown>
asteroides	NNS	<unknown>
.	SENT	.
All	DT	all
patients	NNS	patient
had	VHD	have
low	JJ	low
CD4	NP	<unknown>
cell	NN	cell
count	NN	count
(	(	(
range	VV	range
:	:	:
17-239	CD	@card@
cells/mm(3	NN	<unknown>
)	)	)
)	)	)
and	CC	and
50	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
were	VBD	be
treated	VVN	treat
for	IN	for
tuberculous	JJ	tuberculous
pericarditis	NN	pericarditis
prior	RB	prior
to	TO	to
making	VVG	make
the	DT	the
correct	JJ	correct
diagnosis	NN	diagnosis
of	IN	of
Nocardia	NP	<unknown>
pericarditis	NN	pericarditis
.	SENT	.
This	DT	this
report	NN	report
revisits	VVZ	revisit
the	DT	the
issue	NN	issue
of	IN	of
nocardiosis	NN	<unknown>
as	IN	as
a	DT	a
great	JJ	great
TB	NN	TB
mimicker	NN	mimicker
.	SENT	.
It	PP	it
should	MD	should
always	RB	always
be	VB	be
considered	VVN	consider
in	IN	in
the	DT	the
differential	JJ	differential
diagnosis	NN	diagnosis
among	IN	among
HIV-infected	JJ	HIV-infected
patients	NNS	patient
suspected	VVN	suspect
of	IN	of
having	VHG	have
pericardial	JJ	pericardial
TB	NN	TB
that	WDT	that
is	VBZ	be
failing	VVG	fail
treatment	NN	treatment
.	SENT	.
T.	NP	T.
Mycobacterium	NP	<unknown>
tuberculosis	NN	tuberculosis
of	IN	of
the	DT	the
Beijing	NP	Beijing
Genotype	NP	<unknown>
in	IN	in
Iran	NP	Iran
and	CC	and
the	DT	the
WHO	WP	who
Eastern	NP	Eastern
Mediterranean	NP	Mediterranean
Region	NP	<unknown>
:	:	:
A	DT	a
Meta-Analysis	NN	<unknown>
.	SENT	.
A.	NP	A.
The	NP	The
Beijing	NP	Beijing
genotype	NN	genotype
is	VBZ	be
a	DT	a
distinct	JJ	distinct
genetic	JJ	genetic
lineage	NN	lineage
of	IN	of
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
,	,	,
which	WDT	which
is	VBZ	be
distributed	VVN	distribute
worldwide	RB	worldwide
,	,	,
and	CC	and
may	MD	may
cause	VV	cause
large	JJ	large
outbreaks	NNS	outbreak
of	IN	of
multidrug	NN	<unknown>
resistance-tuberculosis	NN	<unknown>
(	(	(
MDR-TB	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
distribution	NN	distribution
of	IN	of
such	JJ	such
strains	NNS	strain
in	IN	in
the	DT	the
Eastern	NP	Eastern
Mediterranean	NP	Mediterranean
region	NN	region
(	(	(
EMR	NP	Emr
)	)	)
is	VBZ	be
unclear	JJ	unclear
,	,	,
and	CC	and
clarifying	VVG	clarify
the	DT	the
data	NN	data
is	VBZ	be
our	PP$	our
purpose	NN	purpose
apart	RB	apart
from	IN	from
the	DT	the
presence	NN	presence
of	IN	of
Beijing	NP	Beijing
TB	NN	TB
in	IN	in
Iran.We	NP	<unknown>
searched	VVD	search
Published	VVN	publish
literature	NN	literature
from	IN	from
CINAHL	NP	<unknown>
Cochrane	NP	Cochrane
Library	NP	Library
,	,	,
Current	NP	Current
Contents	NP	<unknown>
,	,	,
Database	NN	database
of	IN	of
Abstracts	NP	<unknown>
of	IN	of
Reviews	NPS	Reviews
of	IN	of
Effects	NP	<unknown>
(	(	(
DARE	NP	Dare
)	)	)
,	,	,
ProQuest	NP	<unknown>
Google	NP	<unknown>
Scholar	NP	<unknown>
PubMed	NP	<unknown>
,	,	,
PsycINFO	NP	<unknown>
,	,	,
Thomson	NP	Thomson
Reuters	NP	Reuters
,	,	,
(	(	(
SID	NP	Sid
)	)	)
,	,	,
and	CC	and
Medical	NP	Medical
Library	NP	Library
(	(	(
MedLib	NP	<unknown>
)	)	)
to	TO	to
detect	VV	detect
relevant	JJ	relevant
studies	NNS	study
from	IN	from
the	DT	the
year	NN	year
2000	CD	@card@
to	TO	to
July	NP	July
2015	CD	@card@
with	IN	with
the	DT	the
following	VVG	follow
keywords	NNS	<unknown>
:	:	:
M.	NP	M.
tuberculosis	NN	tuberculosis
,	,	,
Beijing	NP	Beijing
genotype	NN	genotype
,	,	,
EMR	NP	Emr
,	,	,
and	CC	and
drug	NN	drug
resistance	NN	resistance
.	SENT	.
Random-effect	NN	<unknown>
models	NNS	model
were	VBD	be
used	VVN	use
to	TO	to
estimate	VV	estimate
the	DT	the
proportion	NN	proportion
of	IN	of
Beijing	NP	Beijing
strains	NNS	strain
in	IN	in
STATA	NP	Stata
14.	CD	@ord@
Heterogeneity	NN	heterogeneity
was	VBD	be
investigated	VVN	investigate
by	IN	by
subgroup	NN	subgroup
analysis	NN	analysis
and	CC	and
meta-regression.The	NN	<unknown>
meta-prevalence	NN	<unknown>
of	IN	of
Beijing	NP	Beijing
strains	NNS	strain
was	VBD	be
4	CD	@card@
%	NN	%
(	(	(
CI	NP	<unknown>
95% = 3-5	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
prevalence	NN	prevalence
was	VBD	be
different	JJ	different
based	VVN	base
on	IN	on
types	NNS	type
of	IN	of
detection	NN	detection
techniques	NNS	technique
(	(	(
spoligotyping = 4	JJ	<unknown>
%	NN	%
vs.	IN	vs.
other	JJ	other
techniques = 6	NN	<unknown>
%	NN	%
;	:	;
p = 0.003	NP	<unknown>
)	)	)
and	CC	and
years	NNS	year
of	IN	of
study	NN	study
(	(	(
before	IN	before
the	DT	the
year	NN	year
2000 = 2	JJ	<unknown>
%	NN	%
vs.	IN	vs.
after	IN	after
year	NN	year
2000 = 4	JJ	<unknown>
%	NN	%
,	,	,
p = 0.004	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
Beijing	NP	Beijing
family	NN	family
was	VBD	be
most	RBS	most
prevalent	JJ	prevalent
in	IN	in
Iran	NP	Iran
and	CC	and
Pakistan	NP	Pakistan
.	SENT	.
A	DT	a
strong	JJ	strong
relationship	NN	relationship
with	IN	with
drug	NN	drug
resistance	NN	resistance
was	VBD	be
reported	VVN	report
in	IN	in
Pakistan	NP	Pakistan
and	CC	and
Iran	NP	Iran
,	,	,
and	CC	and
an	DT	an
increasing	VVG	increase
trend	NN	trend
was	VBD	be
seen	VVN	see
in	IN	in
Pakistan	NP	Pakistan
.	SENT	.
Additional	JJ	additional
studies	NNS	study
of	IN	of
drug-resistant	JJ	<unknown>
TB	NN	TB
distribution	NN	distribution
among	IN	among
Beijing	NP	Beijing
strains	NNS	strain
in	IN	in
EMR	NP	Emr
countries	NNS	country
are	VBP	be
needed	VVN	need
as	RB	as
well	RB	well
as	IN	as
a	DT	a
time-trend	NN	<unknown>
analysis	NN	analysis
of	IN	of
the	DT	the
Beijing	NP	Beijing
strain	NN	strain
infection	NN	infection
in	IN	in
the	DT	the
region	NN	region
.	SENT	.
T.	NP	T.
Current	NP	Current
immunogenetic	JJ	<unknown>
predisposition	NN	predisposition
to	TO	to
tuberculosis	NN	tuberculosis
in	IN	in
the	DT	the
Moroccan	JJ	Moroccan
population	NN	population
.	SENT	.
A.	NP	A.
Tuberculosis	NP	<unknown>
(	(	(
TB	NN	TB
)	)	)
is	VBZ	be
a	DT	a
serious	JJ	serious
infectious	JJ	infectious
disease	NN	disease
that	WDT	that
kills	VVZ	kill
approximately	RB	approximately
two	CD	two
million	CD	million
people	NNS	people
per	IN	per
year	NN	year
,	,	,
particularly	RB	particularly
in	IN	in
low-	NN	low-
and	CC	and
middle-income	JJ	middle-income
countries	NNS	country
.	SENT	.
Numerous	JJ	numerous
genetic	JJ	genetic
epidemiology	NN	epidemiology
studies	NNS	study
have	VHP	have
been	VBN	be
conducted	VVN	conduct
of	IN	of
many	JJ	many
ethnic	JJ	ethnic
groups	NNS	group
worldwide	RB	worldwide
and	CC	and
have	VHP	have
highlighted	VVN	highlight
the	DT	the
critical	JJ	critical
impact	NN	impact
of	IN	of
the	DT	the
genetic	JJ	genetic
environment	NN	environment
on	IN	on
TB	NN	TB
distribution	NN	distribution
.	SENT	.
Many	JJ	many
candidate	NN	candidate
genes	NNS	gene
associated	VVN	associate
with	IN	with
resistance	NN	resistance
or	CC	or
susceptibility	NN	susceptibility
to	TO	to
TB	NN	TB
have	VHP	have
been	VBN	be
identified	VVN	identify
.	SENT	.
In	IN	in
Morocco	NP	Morocco
,	,	,
where	WRB	where
TB	NN	TB
is	VBZ	be
still	RB	still
a	DT	a
major	JJ	major
public	JJ	public
health	NN	health
problem	NN	problem
,	,	,
various	JJ	various
observations	NNS	observation
of	IN	of
clinical	JJ	clinical
,	,	,
microbiological	JJ	microbiological
and	CC	and
incidence	NN	incidence
distribution	NN	distribution
are	VBP	be
heavily	RB	heavily
affected	VVN	affect
by	IN	by
genetic	JJ	genetic
background	NN	background
and	CC	and
external	JJ	external
environment	NN	environment
.	SENT	.
Morocco	NP	Morocco
has	VHZ	have
almost	RB	almost
the	DT	the
same	JJ	same
clinical	JJ	clinical
profile	NN	profile
as	RB	as
do	VVP	do
other	JJ	other
North	JJ	North
African	JJ	African
countries	NNS	country
,	,	,
mainly	RB	mainly
the	DT	the
increase	NN	increase
in	IN	in
more	JJR	more
extrapulmonary	NN	<unknown>
than	IN	than
pulmonary	JJ	pulmonary
forms	NNS	form
of	IN	of
the	DT	the
diseases	NNS	disease
,	,	,
when	WRB	when
compared	VVN	compare
to	TO	to
European	JJ	European
,	,	,
Asian	JJ	Asian
or	CC	or
American	JJ	American
populations	NNS	population
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
a	DT	a
linkage	NN	linkage
analysis	NN	analysis
study	NN	study
that	WDT	that
examined	VVD	examine
Moroccan	JJ	Moroccan
TB	NN	TB
patients	NNS	patient
identified	VVD	identify
a	DT	a
unique	JJ	unique
chromosome	NN	chromosome
region	NN	region
that	WDT	that
had	VHD	have
a	DT	a
strong	JJ	strong
association	NN	association
with	IN	with
the	DT	the
risk	NN	risk
of	IN	of
contracting	NN	contracting
TB	NN	TB
.	SENT	.
Other	JJ	other
genes	NNS	gene
in	IN	in
the	DT	the
Moroccan	JJ	Moroccan
population	NN	population
that	WDT	that
were	VBD	be
found	VVN	find
to	TO	to
be	VB	be
associated	VVN	associate
seem	VVP	seem
to	TO	to
be	VB	be
involved	VVN	involve
predominantly	RB	predominantly
in	IN	in
modulating	VVG	modulate
the	DT	the
innate	JJ	innate
immunity	NN	immunity
.	SENT	.
In	IN	in
this	DT	this
review	NN	review
,	,	,
we	PP	we
appraise	VVP	appraise
the	DT	the
major	JJ	major
candidate	NN	candidate
genes	NNS	gene
that	WDT	that
have	VHP	have
been	VBN	be
reported	VVN	report
in	IN	in
Moroccan	JJ	Moroccan
immunogenetic	JJ	<unknown>
studies	NNS	study
and	CC	and
discuss	VV	discuss
their	PP$	their
updated	VVN	update
role	NN	role
in	IN	in
TB	NN	TB
,	,	,
particularly	RB	particularly
during	IN	during
the	DT	the
first	JJ	first
phase	NN	phase
of	IN	of
the	DT	the
immune	JJ	immune
response	NN	response
to	TO	to
Mycobacterium	NN	mycobacterium
tuberculosis	NN	tuberculosis
(	(	(
Mtb	NP	<unknown>
)	)	)
infection	NN	infection
.	SENT	.
